WO2019153042A1 - A vaccine composition and uses thereof - Google Patents
A vaccine composition and uses thereof Download PDFInfo
- Publication number
- WO2019153042A1 WO2019153042A1 PCT/AU2019/050089 AU2019050089W WO2019153042A1 WO 2019153042 A1 WO2019153042 A1 WO 2019153042A1 AU 2019050089 W AU2019050089 W AU 2019050089W WO 2019153042 A1 WO2019153042 A1 WO 2019153042A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine composition
- cancer
- seq
- antigen
- adjuvant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 191
- 229960005486 vaccine Drugs 0.000 title claims abstract description 146
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 216
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 188
- 201000011510 cancer Diseases 0.000 claims abstract description 187
- 230000002163 immunogen Effects 0.000 claims abstract description 145
- 230000005875 antibody response Effects 0.000 claims abstract description 72
- 230000008348 humoral response Effects 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 298
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 239
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 238
- 239000000427 antigen Substances 0.000 claims description 226
- 102000036639 antigens Human genes 0.000 claims description 226
- 108091007433 antigens Proteins 0.000 claims description 226
- 239000002671 adjuvant Substances 0.000 claims description 106
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 90
- 125000000539 amino acid group Chemical group 0.000 claims description 52
- 230000027455 binding Effects 0.000 claims description 44
- 230000028993 immune response Effects 0.000 claims description 44
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 40
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 28
- 230000001939 inductive effect Effects 0.000 claims description 26
- 239000002502 liposome Substances 0.000 claims description 24
- 201000001441 melanoma Diseases 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 22
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 22
- 239000000556 agonist Substances 0.000 claims description 21
- 239000011159 matrix material Substances 0.000 claims description 21
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 18
- 101710131520 B melanoma antigen 1 Proteins 0.000 claims description 18
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 18
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 18
- 102000007298 Mucin-1 Human genes 0.000 claims description 18
- 108010008707 Mucin-1 Proteins 0.000 claims description 18
- 229960000814 tetanus toxoid Drugs 0.000 claims description 18
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 17
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 17
- 229930182490 saponin Natural products 0.000 claims description 16
- 150000007949 saponins Chemical class 0.000 claims description 16
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 15
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 15
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 14
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- -1 chitosome Substances 0.000 claims description 11
- 101150029707 ERBB2 gene Proteins 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims description 9
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 9
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 101800001271 Surface protein Proteins 0.000 claims description 9
- 108010017842 Telomerase Proteins 0.000 claims description 9
- 102000002689 Toll-like receptor Human genes 0.000 claims description 9
- 108020000411 Toll-like receptor Proteins 0.000 claims description 9
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 9
- 229940001007 aluminium phosphate Drugs 0.000 claims description 9
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims description 9
- 239000000277 virosome Substances 0.000 claims description 9
- 102000009016 Cholera Toxin Human genes 0.000 claims description 7
- 108010049048 Cholera Toxin Proteins 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 231100000765 toxin Toxicity 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- HUSUHZRVLBSGBO-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydroxide Chemical compound O.[Ca+2].OP([O-])([O-])=O HUSUHZRVLBSGBO-UHFFFAOYSA-L 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 239000006041 probiotic Substances 0.000 claims description 4
- 230000000529 probiotic effect Effects 0.000 claims description 4
- 235000018291 probiotics Nutrition 0.000 claims description 4
- 239000007762 w/o emulsion Substances 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract description 16
- 210000004027 cell Anatomy 0.000 description 87
- 235000001014 amino acid Nutrition 0.000 description 80
- 108020001507 fusion proteins Proteins 0.000 description 65
- 102000037865 fusion proteins Human genes 0.000 description 65
- 150000001413 amino acids Chemical class 0.000 description 64
- 229940024606 amino acid Drugs 0.000 description 62
- 102000004196 processed proteins & peptides Human genes 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 38
- 241000283973 Oryctolagus cuniculus Species 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 35
- 238000002649 immunization Methods 0.000 description 27
- 238000006467 substitution reaction Methods 0.000 description 27
- 230000004927 fusion Effects 0.000 description 26
- 108010033276 Peptide Fragments Proteins 0.000 description 24
- 102000007079 Peptide Fragments Human genes 0.000 description 24
- 238000002965 ELISA Methods 0.000 description 23
- 125000005647 linker group Chemical group 0.000 description 23
- 239000003446 ligand Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 230000003053 immunization Effects 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 102000048362 human PDCD1 Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 235000017709 saponins Nutrition 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 239000000562 conjugate Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 238000011533 pre-incubation Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 7
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 230000005867 T cell response Effects 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 238000012286 ELISA Assay Methods 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002860 competitive effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 5
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 4
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 4
- 101100407306 Mus musculus Cd274 gene Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 201000002313 intestinal cancer Diseases 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000005522 programmed cell death Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001379910 Ephemera danica Species 0.000 description 3
- 102100031351 Galectin-9 Human genes 0.000 description 3
- 101710121810 Galectin-9 Proteins 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 235000009001 Quillaja saponaria Nutrition 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- 240000000031 Achyranthes bidentata Species 0.000 description 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 101001071697 Cavia porcellus Glutathione S-transferase B Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102100031334 Elongation factor 2 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 2
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 2
- 244000274050 Platycodon grandiflorum Species 0.000 description 2
- 241000734672 Polygala senega Species 0.000 description 2
- 241001080798 Polygala tenuifolia Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241001092473 Quillaja Species 0.000 description 2
- 101001026113 Rattus norvegicus Glutathione S-transferase alpha-1 Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 159000000013 aluminium salts Chemical class 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 230000008350 antigen-specific antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000010453 lymph node cancer Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 239000003970 toll like receptor agonist Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940117013 triethanolamine oleate Drugs 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 101710183446 C-type lectin domain family 4 member E Proteins 0.000 description 1
- 102100040839 C-type lectin domain family 6 member A Human genes 0.000 description 1
- 101710125370 C-type lectin domain family 6 member A Proteins 0.000 description 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
- 102100039521 C-type lectin domain family 9 member A Human genes 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 101000888548 Homo sapiens C-type lectin domain family 9 member A Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 239000012648 POLY-ICLC Substances 0.000 description 1
- 101800004191 Peptide P2 Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 108700002563 poly ICLC Proteins 0.000 description 1
- 229940115270 poly iclc Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates generally to a vaccine composition for raising a humoral response to programmed cell death protein 1 (PD1), methods of preparing such composition, and uses thereof for the treatment of conditions characterised by the involvement of PD1, such as cancer.
- PD1 programmed cell death protein 1
- Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. Many tumours co-opt certain immune-checkpoint pathways as a mechanism of immune resistance, particularly against T cells that are specific for tumour antigens.
- the T-cell receptor co-stimulatory pathways have important roles in regulating T- cell activation and tolerance.
- the B7-CD28 superfamily contains both co-stimulatory and inhibitory receptors, including CD28 and programmed cell death protein 1 (PD1).
- PD1 programmed cell death protein 1
- B7-H1 programmed cell death protein 1
- the interaction between PD1 and PD-L1 has been described to negatively regulate the proliferation and the cytokine production of T cells.
- the major role of the PD1 pathway is not at the initial T-cell activation stage, but rather to regulate effector T-cell responses in tissues by downregulating the activity of T cells in order to limit collateral tissue damage.
- PD-L1 is expressed on both malignant cells and infiltrating immune cells in a subset of aggressive B-cell lymphomas.
- the upregulation of PD-L1 expression on myeloma cells has been described to induce T-cell apoptosis and anergy of tumour-specific T cells, as well as enhancing aggressive myeloma-cell characteristics.
- CTL4 Cytotoxic T-lymphocyte-associated antigen 4
- a method of treating a cancer characterised by an involvement of programmed cell death protein 1 (PD1) comprising administering to a subject a vaccine composition for raising a humoral response to PDl, wherein the vaccine composition comprises an effective amount of an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PDl.
- PD1 programmed cell death protein 1
- the method further comprises administering to the subject a second immunogen in an effective amount that induces an immune response against a cancer-associated antigen.
- the method further comprises administering to the subject an antibody, or an antigen-binding fragment thereof, that specifically binds to a cancer-associated antigen.
- a vaccine composition in the preparation of a medicament for the treatment of a cancer characterised by an involvement of PD1, wherein the vaccine composition comprises an effective amount of an immunogen for inducing an antibody response in which the antibody binds to a B cell epitope of PD1, as herein described.
- the medicament is formulated for administration with a second immunogen, wherein the second immunogen is present in an effective amount to induce an immune response in a subject against a cancer-associated antigen, as herein described.
- a vaccine composition for use in treating a cancer characterised by an involvement of PD1, wherein the vaccine composition comprises an effective amount of an immunogen for inducing an antibody response in which the antibody binds to a B cell epitope of PD1, as herein described.
- the composition further comprises an effective amount of a second immunogen for inducing an immune response against a cancer-associated antigen, as herein described.
- a vaccine composition for raising a humoral response to PD1, wherein the vaccine composition comprises an effective amount of an immunogen for inducing an antibody response in which the antibody binds to a B cell epitope of PD1, as herein described.
- the composition further comprises an effective amount of a second immunogen for inducing an immune response against a cancer-associated antigen, as herein described.
- a vaccine composition for raising a humoral response to PD1, wherein the composition comprises an immunogen comprising a peptide sequence that induces an antibody response in which the antibody binds to a B cell epitope of PD1, wherein the peptide sequence comprises at least 8 contiguous amino acid residues of the amino acid sequences selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43, 49 and amino acid sequences having at least 70% sequence identity to any of the foregoing, and wherein the amino acid sequence of the immunogen is not identical to a continuous stretch of at least SO amino acid residues of PD1.
- a method of treating a condition characterised by an involvement of PD1 comprising administering to a subject in need thereof the vaccine composition as herein described.
- a pharmaceutical composition comprising the vaccine composition as herein described and a pharmaceutically acceptable excipient.
- a pharmaceutical composition comprising the vaccine composition as herein described for the treatment of a condition characterised by an involvement of PD1.
- Figure 1 is a schematic diagram of an NuPage LDS-Page gel showing purified GST-B cell epitopes of PD1. The gel is stained using Simply Blue Safe Stain (Thermo Scientific).
- Figure 2 shows the capacity of the identified B cell epitope of mouse PD1 (SEQ ID NO: 119) to inhibit the binding of an anti-mouse-PDl monoclonal antibody (mAb) to recombinant mouse PD1 (ELISA OD values, 450 urn).
- mAb monoclonal antibody
- Figure 3 shows the capacity of the B cell epitope (SEQ ID NO: 119) to inhibit the binding of anti-mouse PD-1 mAb to Jurkat T cells expressing mouse PD-1.
- Figure 4 shows the antibody titre of anti-mPDl IgG antibodies in the serum of mice immunised with a mPDl B cell epitope (SEQ ID NO:119)-CRM conjugate, the results showing a clear antibody response to the mPD1 B cell epitope-CRM conjugate, as illustrated by an increased antibody titre at 41 days (BA1), 62 days (BA2), 83 days (BA3) and 104 days (BA4) after the first immunization at day 0 ( Figure 4).
- Figure 5 shows the inhibitory activity of JT-mPDl in a cellular assay.
- Jurkat T cells expressing mPDl were used in a binding assay to examine the binding of an anti-mPDl mAb alone or after pre-incubation with different concentrations of JT-mPDl. Significant differences are denoted by asterisks.
- Figure 6 shows binding of anti-JT-mPDl-IgG to recombinant mPDl expressed on Jurkat T cells.
- Figure 7 shows anti-tumor activity of anti-JT-mPDl IgG in a syngeneic mouse tumor model.
- BLAB/c mice were grafted with Her-2-expressing mammary carcinoma D2F2/E2 cells.
- the bars indicate the average weight of the tumors explanted from mice in each group at sacrifice.
- Corresponding macroscopic images of representative explanted tumors are shown below each bar. Significant differences are denoted by asterisks.
- Figure 8 shows the binding of a polyclonal anti-PDl antibody (Sino Biological Inc.; Cat. No. 10377-RP03) to each of the 12-mer linear peptide fragments of human PD1.
- the amino acid sequences of the fragments (peptide sequences) are shown along the x-axis and represent (from left to right of the x-axis) SEQ ID NOs:2-54 and 62 of Table 1.
- the data show the optical density (OD) readings (y-axis) from the enzyme-linked immunosorbent assay (ELISA) at 450 nm.
- Figure 9 shows the binding of affinity purified anti-peptide sequence antibodies (from immunised rabbit antisera, diluted 1:25,000) to native human PD1.
- the linear peptide fragments to which the rabbits were immunized are shown along the x-axis.
- the data show the optical density (OD) readings (y-axis) at 450 nm.
- SEQ ID NO: correspond numerically to the sequence identifiers ⁇ 400>1, ⁇ 400>2, etc.
- the present disclosure is predicated, at least in part, on the inventors' surprising finding that immunization with a peptide sequence of a B cell epitope of the checkpoint antigen PD1 is capable of raising an antibody response in which the antibodies bind to the native PD1 protein.
- the present inventors also surprisingly found that immunization with the PD1 -derived B cell epitope did not appear to give rise to any adverse side effects such as weight loss or inflammatory reactions.
- a method of treating a cancer characterised by an involvement of programmed cell death protein 1 (PD1) comprising administering to a subject a vaccine composition for raising a humoral response to PD1 wherein the vaccine composition comprises an effective amount of an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PD1.
- PD1 programmed cell death protein 1
- the present disclosure is also predicated, at least in part, on the inventors' unexpected finding that short peptide sequences of at least 8 contiguous amino acid residues of PD1, when administered to a subject, can induce an antibody response in which the antibodies bind to a B cell epitope of PD1.
- a vaccine composition for raising a humoral response to PD1, wherein the composition comprises an immunogen comprising a peptide sequence that induces an antibody response in which the antibody binds to a B cell epitope of PD1, wherein the peptide sequence comprises at least 8 contiguous amino acid residues of the amino acid sequences selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43, 49 and amino acid sequences having at least 70% sequence identity to any of the foregoing, and wherein the amino acid sequence of the immunogen is not identical to a continuous stretch of at least 50 amino acid residues of PD1.
- immunogen is used herein to describe a peptide that is capable of raising an immune response, including a humoral (antibody) response, in vivo.
- peptide and “polypeptide” are used interchangeably herein in their broadest sense to refer to a molecule of two or more amino acid residues, or amino acid analogs.
- the amino acid residues may be linked by peptide bonds, or alternatively by other bonds, e.g. ester, ether etc., but in most cases will be linked by peptide bonds.
- amino acid or amino acid residue
- amino acid analogs is to be understood as a non-naturally occurring amino acid differing from its corresponding naturally occurring amino acid at one or more atoms.
- an amino acid analog of cysteine may be homocysteine.
- the immunogen comprises at least 9, preferably at least 10, more preferably at least 11 contiguous amino acid residues of the amino acid sequences selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49 and amino acid sequences having at least 70% sequence identity to any of the foregoing.
- the peptide sequence comprises at least 8 contiguous amino acid residues of the amino acid sequences selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49. In an embodiment, the peptide sequence comprises at least 9 contiguous amino acid residues of the amino acid sequences selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49. In an embodiment, the peptide sequence comprises at least 10 contiguous amino acid residues of the amino acid sequences selected from the group consisting of SEQ ID NOs:9, 10, 14, 24,
- the peptide sequence comprises at least 11 contiguous amino acid residues of the amino acid sequences selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49. In an embodiment, the peptide sequence is selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28,
- the immunogen consists, or consists essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43, 49 and 58-63.
- the peptide sequence further comprises one or more (i.e., 1, 2, 3, 4, 5, 6, 7, 8. 9, 10, 11, 12, 13, 14, 15, and so on) additional amino acid residues at the N- and/or C terminus of the amino acid sequence selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43, 49 and amino acid residues sequences having at least 70% sequence identity to any of the foregoing.
- the peptide sequence further comprises one or more amino acid residues at the N- and/or C terminus of the amino acid sequence selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49.
- one or more additional amino acid residues is meant at least 1, preferably at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, preferably at least 9, preferably at least 10, preferably at least 11, preferably at least 12, preferably at least 13 or preferably at least 14 additional amino acid residues.
- the peptide sequence comprises at least 13 contiguous amino acid residues of SEQ ID NO:l.
- the peptide sequence comprises at least 14 contiguous amino acid residues of SEQ ID NO:l.
- the peptide sequence comprises at least IS contiguous amino acid residues of SEQ ID NO:l.
- the peptide sequence comprises at least 16 contiguous amino acid residues of SEQ ID NO:l. In an embodiment, the peptide sequence comprises at least 17 contiguous amino acid residues of SEQ ID NO:l. In an embodiment, the peptide sequence comprises at least 18 contiguous amino acid residues of SEQ ID NO:l. In an embodiment, the peptide sequence will comprise an amino acid sequence selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49, and will further comprise one or more amino acid residues that extend from the C -terminus of the peptide sequence in SEQ ID NO: 1.
- the peptide sequence will comprise an amino acid sequence selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49, and will further comprise one or more amino acid residues that extend from the N-terminus of the peptide sequence in SEQ ID NO: 1.
- the peptide sequence will comprise an amino acid sequence selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49, and will further comprise one or more amino acid residues that extend from the C -terminus and one or more amino acid residues that extend from the N-terminus of the peptide sequence in SEQ ID NO: 1.
- the peptide sequence comprises, consists or consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:S8 to 63 and amino acid sequences having at least 70% sequence identity to any of the foregoing.
- the peptide sequence comprises, consists or consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:58 to 63.
- the peptide sequence comprises, consists or consists essentially of an amino acid sequence of SEQ ID NO:58.
- the peptide sequence comprises, consists or consists essentially of an amino acid sequence of SEQ ID NO:59.
- the peptide sequence comprises, consists or consists essentially of an amino acid sequence of SEQ ID NO:60. In another embodiment, the peptide sequence comprises, consists or consists essentially of an amino acid sequence of SEQ ID NO:61. In another embodiment, the peptide sequence comprises, consists or consists essentially of an amino acid sequence of SEQ ID NO:62. In another embodiment, the peptide sequence comprises, consists or consists essentially of an amino acid sequence of SEQ ID NO:63.
- an immunogen comprising a peptide sequence of at least 8 contiguous amino acid residues of the amino acid sequence of SEQ ID NOs:9 produces a higher anti-PDl antibody titre when administered in vivo, compared to the other peptide sequences disclosed herein.
- the peptide sequence comprises at least 8 contiguous amino acid residues of SEQ ID NOs:9, or an amino acid sequence having at least 70% sequence identity thereto.
- the peptide sequence is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:43, and amino acid sequences having at least 70% sequence identity thereto.
- the peptide sequence is selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:43.
- the immunogen consists, or consists essentially of, an amino acid sequence selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:43.
- the immunogen comprises at least two of the peptide sequences disclosed herein.
- each of the at least two peptide sequences induces an antibody response in vivo in which the antibody binds to a different B cell epitopes of PD1.
- the immunogen comprises at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, or more preferably at least 9 of the peptide sequences described herein.
- the immunogen comprises SEQ ID NO:9 and SEQ ID NO:43.
- the immunogen comprises at least two peptide sequences
- the at least two peptide sequences may have a branched or linear configuration.
- the term "fusion protein" typically refers to a polypeptide composed of two or more peptide sequences linked to one another.
- the fusion protein comprises two or more peptide sequences linked to one another end-to-end.
- the fusion protein comprises two or more peptide sequences linked to one another in a linear configuration via a suitable linking moiety, also referred to herein as a linker.
- suitable linking moiety also referred to herein as a linker.
- Suitable methods of linking peptide sequences will be familiar to persons skilled in the art, illustrative examples of which include peptide (amide) bonds and linkers.
- the term "linker” refers to a short polypeptide sequence interposed between any two neighboring peptide sequences as herein described.
- the linker is a polypeptide linker of 1 to 10 amino acids, preferably 1, 2, 3, 4 or 5 naturally or non-naturally occurring amino acids.
- the linker is a carbohydrate linker. Suitable carbohydrate linkers will be known to persons skilled in the art.
- the fusion protein comprises one or more peptidic or polypeptidic linker(s) together with one or more other non-peptidic or non- polypeptidic linker(s).
- linkers may be incorporated in the same fusion peptide as deemed appropriate.
- the linker will be advantageously incorporated such that its N-terminal end is bound via a peptide bond to the C -terminal end of the one peptide sequence, and its C-terminal end via a peptide bond to the N-terminal end of the other peptide sequence.
- the individual peptide sequences within the fusion protein may also have one or more amino acids added to either or both ends, preferably to the C-terminal end.
- linker or spacer amino acids may be added to the N- or C-terminus of the peptides or both, to link the peptides and to allow for convenient coupling of the peptides to each other and/or to a delivery system such as a carrier molecule serving as an anchor.
- a suitable peptidic linker is LP (leucine-proline).
- the immunogen may suitably comprise a fusion protein comprising, consisting, or consisting essentially of any combination of two or more of the peptide sequences disclosed herein.
- the fusion protein comprises, consists, or consists essentially of at least three of the peptide sequences disclosed herein.
- Fusion protein may comprise the two or more of the peptide sequences disclosed herein in any order, illustrative examples of which include SEQ ID NO:9-10, SEQ ID NO:10-9, SEQ ID NO:9-14, SEQ ID NO:14-9, SEQ ID NO:10-14, SEQ ID NO:14-10, SEQ ID NO:9-28, SEQ ID NO: 10-28, SEQ ID NO: 14-28, SEQ ID NO:28-9, SEQ ID NO:28-10, SEQ ID NO:28-14, SEQ ID NO:9-29, SEQ ID NO: 10-29, SEQ ID NO: 14-29, SEQ ID NO:28-29, SEQ ID NO:29-9, SEQ ID NO:29-10, SEQ ID NO:29-14, SEQ ID NO:29-28, SEQ ID NO:9-10-14, SEQ ID NO:9-14-10, SEQ ID NO:14-9-10, SEQ ID NO:14-10-9, SEQ ID NO:10-14-9, SEQ ID NO:10-9-14,
- the fusion protein comprises, consists, or consists essentially of, peptide sequences of SEQ ID NO:9 and SEQ ID NO:43.
- the immunogen comprises an amino acid sequence selected from the group consisting of SEQ ID NO:56 and SEQ ID NO:57.
- the immunogen consists, or consists essentially of, an amino acid sequence selected from the group consisting of SEQ ID NO:56 and SEQ ID NO:57.
- fusion proteins comprising at least two of the peptide sequences disclosed herein, concatenated two or more times in tandem repeat.
- fusion proteins contemplated herein may comprise two or more tandem repeats of the peptide sequences of at least 8 contiguous amino acid residues of the amino acid sequences selected from the group consisting of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49 and amino acid sequences having at least 70% sequence identity to any of the foregoing.
- Suitable methods of preparing a fusion protein, as herein described, would be familiar to persons skilled in the art.
- An illustrative example includes peptide synthesis that involves the sequential formation of peptide bonds linking each peptide sequence, as herein described, to its respectively neighboring peptide sequence, and recovering said fusion peptide.
- Illustrative examples include the methods described in "Amino Acid and Peptide Synthesis” (Oxford Chemistry Primers; by John Jones, Oxford University Press).
- Synthetic peptides can also be made by liquid-phase synthesis or solid-phase peptide synthesis (SPPS) on different solid supports ⁇ e.g. polystyrene, polyamide, or PEG). SPPS may incorporate the use of F-moc (9H-fluoren-9-ylmethoxycarbonyl) or t-Boc (tert- Butoxycarbonyl).
- Custom peptides are also available from a number of commercial manufacturers.
- the fusion protein may be prepared by recombinant methodology.
- a nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein can be transfecting into a suitable host cell capable of expressing said nucleic acid sequence, incubating said host cell under conditions suitable for the expression of said nucleic acid sequence, and recovering said fusion protein.
- Suitable methods for preparing a nucleic acid molecule encoding the fusion protein will also be known to persons skilled in the art, based on knowledge of the genetic code, possibly including optimizing codons based on the nature of the host cell ⁇ e.g. microorganism) to be used for expressing and/or secreting the recombinant fusion protein.
- Suitable host cells will also be known to persons skilled in the art, illustrative examples of which include prokaryotic cells ⁇ e.g., E. colt) and eukaryotic cells ⁇ e.g., P. pastoris).
- prokaryotic cells ⁇ e.g., E. colt
- eukaryotic cells ⁇ e.g., P. pastoris
- encode refers to the capacity of a nucleic acid to provide for another nucleic acid or a polypeptide.
- a nucleic acid sequence is said to "encode” a polypeptide if it can be transcribed and/or translated, typically in a host cell, to produce the polypeptide or if it can be processed into a form that can be transcribed and/or translated to produce the polypeptide.
- Such a nucleic acid sequence may include a coding sequence or both a coding sequence and a non-coding sequence.
- the terms "encode,” "encoding” and the like include an RNA product resulting from transcription of a DNA molecule, a protein resulting from translation of an RNA molecule, a protein resulting from transcription of a DNA molecule to form an RNA product and the subsequent translation of the RNA product, or a protein resulting from transcription of a DNA molecule to provide an RNA product, processing of the RNA product to provide a processed RNA product ⁇ e.g., mRNA) and the subsequent translation of the processed RNA product.
- the nucleic acid sequence encoding the peptide sequences, as herein described, or the fusion proteins, as herein described are codon-optimised for expression in a suitable host cell.
- the nucleic acid sequences can be human codon-optimised. Suitable methods for codon optimisation would be known to persons skilled in the art, such as using the "Reverse Translation” option of 'Gene Design” tool located in "Software Tools” on the John Hopkins University Build a Genome website.
- the peptide sequences can be linked to one another within the fusion peptide by any means known to persons skilled in the art.
- the terms “link” and “linked” include direct linkage of two peptide sequences via a peptide bond; that is, the C-terminus of one peptide sequence is covalently bound via a peptide bond to the N-terminal of another peptide sequence.
- the terms “link” and “linked” also include within their meaning the linkage of two peptide sequences via an interposed linker element.
- linker-mediated coupling from the C-terminus of the fusion protein, since linker coupling from the N-terminus may, in some instances, have a negative influence on the desired immune response to be elicited.
- the at least two peptide sequences in a fusion protein are linked to one another via a non-native linker peptide sequence.
- the peptide sequences may be linked to one another within the fusion peptide in such a way as to ensure the fusion protein comprises an amino acid sequence that is not identical to a continuous stretch of at least 40, preferably at least SO, amino acid residues of native PDl .
- a homogeneous formulation can be achieved in which only one kind of fusion protein is present.
- the elements of the fusion protein ⁇ i.e. the peptide sequences capable of inducing antibody responses in which the antibodies bind to B cell epitopes of native PDl) may be the same in every fusion protein and can be chosen (or chosen and modified) such that undesired intra- and inter- polypeptide interactions are minimized.
- the ratio of the at least two peptide sequences present in the vaccine composition may ultimately be dictated by the ratio of these peptides in the fusion peptide. This means that any desired ratio for eliciting an antibody response to PD1 can be easily and reliably fixed at the level of fusion protein construction and design.
- a fusion peptide may comprise an amino acid sequence of any suitable length, as long as the fusion peptide retains the ability or capacity to induce an antibody response in vivo in which the antibody binds to a B cell epitope of native PD1.
- the fusion peptide is at least 16 (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or more) amino acids in length.
- the fusion peptide is from about 16 amino acids to about 40 amino acids in length.
- the fusion peptide is from about 16 amino acids to about 36 amino acids in length.
- the fusion peptide is from about 16 amino acids to about 24 amino acids in length.
- the fusion peptide is about 24 amino acids in length.
- B cell epitope refers to a part of a molecule that is recognized by an antibody.
- a “B cell epitope” is to be understood as being a smaller subsequence of an antigen that is capable of being recognized (bound) by an antibody.
- an antigen may contain multiple B cell epitopes, and therefore may be bound by multiple distinct antibodies.
- a single epitope may also be bound by multiple antibodies having different antigen-binding specificity and/or affinity. Multiple antibodies of different subclasses may also bind to the same epitope.
- the immunogen will comprise at least one peptide sequence that, when administered to a subject, will induce an antibody response such that the antibody binds to a B cell epitope of PD1, preferably to a B cell epitope of a native PD1 molecule; that is, to the PD1 antigen as it exists in nature.
- the at least one peptide sequence of the immunogen will induce an antibody response such that the antibody binds to a B cell epitope of the extracellular domain of a native PD1 molecule.
- the B cell epitope to which an antibody is raised will be an epitope located within the extracellular domain of the native antigen.
- the immunogen comprises an autologous B cell epitope of PD1; that is, a B cell epitope of PD1 having an amino acid sequence derived from a PD1 molecule of the same species as the subject to be treated.
- the terms “native” and “natural” refer to the form of a molecule as normally occurring in nature.
- the native sequence of PD1 comprises the amino acid sequence of SEQ ID NO:l.
- a "non-native" sequence, including a “non-native linker” is any amino acid sequence not belonging to native sequence of PD1.
- the present disclosure also extends to PD1 isoforms of non-human species, including non-human primate, canine, feline, equine, bovine, porcine and murine isoforms of PD1.
- the non-human PD1 isoform is a mouse PD1, an illustrative example of which comprises the amino acid sequence of Uniprot No. Q02242, incorporated herein by reference in its entirety..
- a peptide sequence having at least 70% sequence identity to any one of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49, as herein described, is also referred to herein as a "functional variant".
- a “functional variant”, as used herein, means a peptide sequence that has a different amino acid sequence to a peptide to which it is compared (i.e., a comparator), which may include a natural (i.e., native) sequence or a synthetic variant thereof, yet retains the ability to induce an antibody response in vivo in which the antibody binds to a B cell epitope of PD1.
- Suitable methods of determining whether a functional variant retains the ability to induce an antibody response in vivo in which the antibody binds to a B cell epitope of native PD1 will be familiar to persons skilled in the art, illustrative examples of which are described elsewhere herein.
- the antibody response elicited by a fusion protein comprising a non-derivatized, native B cell epitope of PD1 can be compared, using the same assay, to that elicited by a fusion protein comprising the variant of the native B cell epitope.
- the amino acid substitution can be regarded as functionally equivalent. If the derivatized immune response is superior to the non-derivatized one, then the amino acid substitution can be regarded as improved.
- a functional variant may include an amino acid sequence that differs from the native peptide sequence by one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or more) amino acid substitutions, wherein said difference does not, or does not completely, abolish the capacity of the variant to induce an antibody response in which the antibody binds to a B cell epitope of PD1.
- the functional variant may comprise amino acid substitutions that enhance the capacity of the peptide sequence to induce an antibody response in which the antibody binds to a B cell epitope of PD1, as compared to the native peptide sequence.
- the functional variant differs from the native peptide sequence by one or more conservative amino acid substitutions.
- conservative amino acid substitution refers to changing amino acid identity at a given position to replace it with an amino acid of approximately equivalent size, charge and/or polarity.
- conservative substitutions of amino acids include the following 8 substitution groups (designated by the conventional one-letter code): (1) M, I, L, V; (2) F, Y, W; (3) K, R, (4) A, G; (5) S, T; (6) Q, N; (7) E, D; and (8) C, S.
- Reference to "at least 70%” includes 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity any one of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49, for example, after optimal alignment or best fit analysis.
- the functional variant has at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99% or preferably 100% sequence identity to any one of SEQ ID NOs:9, 10, 14, 24, 28, 29, 42, 43 and 49, for example, after optimal alignment or best fit analysis.
- identity means that at any particular amino acid residue position in an aligned sequence, the amino acid residue is identical between the aligned sequences.
- similarity indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences.
- leucine may be substituted for an isoleucine or valine residue. This may be referred to as conservative substitution.
- the amino acid sequences may be modified by way of conservative substitution of any of the amino acid residues contained therein, such that the modification has no effect on the binding specificity or functional activity of the modified polypeptide when compared to the unmodified polypeptide.
- sequence identity with respect to a peptide sequence relates to the percentage of amino acid residues in the candidate sequence which are identical with the residues of the corresponding peptide sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentage homology, and not considering any conservative substitutions as part of the sequence identity. Neither N- or C- terminal extensions, nor insertions shall be construed as reducing sequence identity or homology. Methods and computer programs for performing an alignment of two or more amino acid sequences and determining their sequence identity or homology are well known to persons skilled in the art. For example, the percentage of identity or similarity of two amino acid sequences can be readily calculated using algorithms, for example, BLAST, FASTA, or the Smith- Waterman algorithm.
- similarity means an exact amino acid to amino acid comparison of two or more peptide sequences or at the appropriate place, where amino acids are identical or possess similar chemical and/or physical properties such as charge or hydrophobicity. A so-termed “percent similarity” then can be determined between the compared peptide sequences.
- identity refers to an exact amino acid to amino acid correspondence of two peptide sequences.
- Two or more peptide sequences can also be compared by determining their "percent identity".
- the percent identity of two sequences may be described as the number of exact matches between two aligned sequences divided by the length of the shorter sequence and multiplied by 100.
- An approximate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be extended to use with peptide sequences using the scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA, and normalized by Gribskov, Nucl. Acids Res. 14(6):6745-6763 (1986). Suitable programs for calculating the percent identity or similarity between sequences are generally known in the art.
- Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WL USA) or by inspection and the best alignment ⁇ i.e., resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected.
- GAP Garnier et al.
- BESTFIT Pearson FASTA
- FASTA Pearson's Alignment of sequences
- TFASTA Pearson's Alignment of Altschul et al.
- a detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel et al., "Current Protocols in Molecular Biology", John Wiley & Sons Inc, 1994-1998, Chapter 15.
- a functional variant includes amino acid substitutions and/or other modifications in order to increase the stability of the immunogen and/or to increase the solubility of the immunogen to enhance its ability to induce an antibody response in vivo. Suitable modifications will be familiar to persons skilled in the art, illustrative examples of which are described elsewhere herein.
- Peptide sequences disclosed herein can be synthetically produced by chemical synthesis methods which are well known in the art, either as an isolated peptide sequence or as a part of another peptide or polypeptide.
- peptide sequences can be produced in a microorganism which produces the (recombinant) peptide sequence or sequences, which can then be isolated and, if desired, further purified.
- the peptide sequences can be produced in microorganisms such as bacteria, yeast or fungi, in eukaryote cells such as a mammalian or an insect cell, or in a recombinant virus vector such as adenovirus, poxvirus, herpesvirus, Simliki forest virus, baculovirus, bacteriophage, Sindbis virus or sendai virus.
- Suitable bacteria for producing the peptide sequences will be familiar to persons skilled in the art, illustrative examples of which include E. coli, B.subtilis or any other bacterium that is capable of expressing the peptide sequences.
- yeast types for expressing the peptide sequences include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Candida, Pichia pastoris or any other yeast capable of expressing peptides.
- Corresponding methods are well known in the art.
- methods for isolating and purifying recombinantly produced peptide sequences are well known in the art and include, for example, gel filtration, affinity chromatography and ion exchange chromatography.
- a fusion polypeptide may be made wherein the at least one peptide sequence is translationally fused (covalently linked) to a heterologous polypeptide which enables isolation by affinity chromatography.
- Typical heterologous polypeptides are His-Tag (e.g. His 6 . 6 histidine residues), GST-Tag (Glutathione-S-transferase) etc.
- His-Tag e.g. His 6 . 6 histidine residues
- GST-Tag Glutathione-S-transferase
- the fusion polypeptide may comprise a cleavage site at the junction between the peptide sequence and the heterologous polypeptide.
- the cleavage site consists of an amino acid sequence that is cleaved with an enzyme specific for the amino acid sequence at the site (e.g. proteases).
- peptide sequences disclosed herein may be suitably modified at or nearby their N- and/or C -termini so that at said positions a cysteine residue is bound thereto.
- phage libraries and/or peptide libraries are also suitable, for instance, produced by means of combinatorial chemistry or obtained by means of high throughput screening techniques for the most varying structures (see, for example, Display: A Laboratory Manual by Carlos F. Barbas (Editor), et al. ⁇ and Willats WG Phage display: practicalities and prospects. Plant Mol. Biol. 2002 December; 50(6): 837-54).
- an illustrative example of a suitable functional variant is the peptide sequence of SEQ ID NO:61, noting that SEQ ID NO:61 differs from the corresponding native human PD1 peptide fragment (SEQ ID NO:42) by substituting the cysteine residue at position 3 of SEQ ID NO:42 with a serine residue.
- the functional variant comprises, consists or consists essentially of an amino acid sequence of SEQ ID NO:61.
- the antibody response to the peptide sequences disclosed herein may be further enhanced by incorporating into the immunogen a Th cell epitope that promotes the release of cytokines that assist in bypassing MHC restriction (i.e., a promiscuous Th cell epitope).
- a promiscuous Th cell epitope i.e., a promiscuous Th cell epitope.
- the immunogen further comprises a promiscuous T helper (Th) cell epitope.
- Suitable promiscuous Th cell epitopes will be known to persons skilled in the art, illustrative examples of which include measles virus fusion protein (MVF; KLLSLI GVIVHRLEGVE; SEQ ID NO: 110), tetanus toxoid (TT; NSVDDALINSTIYSYFPSV; SEQ ID NO: 111), TT1 (PGINGKAIHLVNNQSSE; SEQ ID NO: 112); TT peptide P2 (QYT ANS KFIG1TEL; SEQ ID NO: 113); TT peptide P30 (FNNFTVSFWLRVPKVSASHLE; SEQ ID NO: 114); MVF' (LSEIKGVIVHRLEGV; SEQ ID NO: 115); Hepatitis B virus (HBV; FFLLTRILTIPQSLN; SEQ ID NO: 116); circumsporozoite protein (CSP; TCGVGVRVRSRVNAANKKPE1; SEQ ID NO: 117
- the promiscuous Th epitope is from about 8 to about 36, preferably from about 8 to about 24, more preferably from about 8 to 22, most preferably from about 8 to about 22 amino acids in length.
- the promiscuous Th cell epitope is linked to a peptide sequences or fusion protein, as herein described, to form a chimeric peptide. Suitable linkers will be familiar to persons skilled in the art, illustrative examples of which are described elsewhere herein.
- An immunogen will typically comprise at least one peptide sequence (e.g., 1, 2, 3, 4, S, 6, 7, 8, 9, 10, 11 or more peptide sequences) that induces an antibody response in vivo in which the antibody binds to a B cell epitope of PD1, preferably to a B cell epitope of a native PD1 molecule.
- the at least one peptide sequence may comprise (i) a B cell epitope of PD1, or a functional variant thereof, (ii) a mimotope of a PD1 B cell epitope or (iii) a combination of any of the foregoingln an embodiment, the immunogen comprises at least one B cell epitope of PD1, or a functional variant thereof.
- the immunogen comprises at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, preferably at least 9, preferably at least 10, preferably at least 11 or more preferably at least 12 non-contiguous B cell epitopes of PD1, or functional variants thereof.
- the immunogen comprises, consists or consists essentially of one B cell epitope of PD1, or a functional variant thereof.
- the immunogen comprises, consists or consists essentially of two noncontiguous B cell epitopes of PD1, or functional variants thereof.
- the immunogen comprises, consists or consists essentially of three noncontiguous B cell epitopes of PD1, or functional variants thereof.
- B cell epitope refers to a part of a molecule that is recognized by an antibody.
- a “B cell epitope” is to be understood as being a smaller subsequence of an antigen that is capable of being recognized (bound) by an antibody.
- an antigen may contain multiple B cell epitopes, and therefore may be bound by multiple distinct antibodies.
- a single epitope may also be bound by multiple antibodies having different antigen-binding specificity and/or affinity. Multiple antibodies of different subclasses may also bind to the same epitope.
- the immunogen will comprise at least one peptide sequence that, when administered to a subject, will induce an antibody response such that the antibody binds to a B cell epitope of a native PD1 molecule; that is, to the PD1 antigen as it exists in nature.
- the at least one peptide sequence of the immunogen will induce an antibody response such that the antibody binds to a B cell epitope of the extracellular domain of a native PD1 molecule.
- the B cell epitope to which an antibody is raised will be an epitope located within the extracellular domain of the native antigen.
- the immunogen comprises an autologous B cell epitope of PD1; that is, a B cell epitope of PD1 having an amino acid sequence derived from a PD1 molecule of the same species as the subject to be treated.
- a sub-sequence of an antigen may be identified with a high degree of accuracy as being, or comprising, a B cell epitope by using established computer programs that compare the subsequence in question with a database of known sequences and/or partial sequences known to be recognized by antibodies encoded by the human or mouse germline.
- a B cell epitope may be identified by computer-aided analysis using various combinations of correlates of antigenicity such as surface accessibility, chain flexibility, hydropathy/hydrophilicity profiles, predicted secondary structure, etc.
- an antigen may be identified as comprising a B cell epitope by immunizing an animal with the antigen in question at least once, allowing a humoral immune response to mount and then testing the serum of the animal for antibodies that specifically bind to at least a part of the administered antigen using, for example, an enzyme linked immunosorbant assay (ELISA), a radioimmunoassay, a Western blot analysis or a dot-blot analysis.
- ELISA enzyme linked immunosorbant assay
- radioimmunoassay a radioimmunoassay
- Western blot analysis or a dot-blot analysis.
- the B cell epitope is a B cell epitope of human PD1 (SEQ ID NO:l). Tables 1 and 2, above, set out illustrative examples of B cell epitopes of human PD1.
- the B cell epitope of PD1 is selected from the group consisting of SEQ ID NOs:2-109. In a further embodiment, the B cell epitope of PD1 is selected from the group consisting of SEQ ID NOs:9, 43 and 57. In another embodiment disclosed herein, the B cell epitope of PD1 is a functional variant of the B cell epitopes of PD1, illustrative examples of which are provided in Tables 1 and 2 herein ( . ⁇ ?., SEQ ID NOs:2- 109).
- the present disclosure also extends to PD1 isoforms of non-human species, including non-human primate, canine, feline, equine, bovine, porcine and murine isoforms of PD1.
- the non-human PD1 isoform is a mouse PD1, an illustrative example of which comprises the amino acid sequence of Uniprot No. Q02242, incorporated herein by reference in its entirety..
- the term "functional variant” means a peptide sequence that has a different amino acid sequence to a peptide to which it is compared (i.e., a comparator), which may include a native sequence or an isoform thereof, yet retains the ability, when administered, to induce an antibody response in which the antibody binds to a B cell epitope of PD1.
- Functional variant include fragments of a PD1 B cell epitope.
- a functional fragment of a PD1 B cell epitope can be any suitable length, as long as the fragment retains the ability to induce an antibody response in which the antibody binds to a B cell epitope of PD1, preferably an antibody response in which the antibody binds to a B cell epitope of native PD1.
- the functional variant is a fragment of the PD1 protein of SEQ ID NO:l comprising, consisting or consisting essentially of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2-109.
- the functional variant is a fragment of the PD1 protein of SEQ ID NO:l comprising, consisting or consisting essentially of the amino acid sequence selected from the group consisting of SEQ ID NOs:9, 43 and 57.
- Suitable methods of determining whether a variant of a B cell epitope of PD1 retains the ability to induce an antibody response in which the antibody binds to a B cell epitope of native PD1 will be familiar to persons skilled in the art, illustrative examples of which are described elsewhere herein.
- the antibody response elicited by a fusion protein comprising a non-derivatized, native B cell epitope of PD1 can be compared, using the same assay, to that elicited by a fusion protein comprising the variant of the native B cell epitope.
- the amino acid substitution can be regarded as functionally equivalent. If the derivatized immune response is superior to the non- derivatized one, then the amino acid substitution can be regarded as improved.
- the term "functional variant” also includes an amino acid sequence that differs from the native sequence by one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or more) amino acid substitutions, wherein said difference does not, or does not completely, abolish the capacity of the variant to induce an antibody response in which the antibody binds to a B cell epitope of PD1.
- the functional variant may comprise amino acid substitutions that enhance the capacity of the immunogen to induce an antibody response in which the antibody binds to a B cell epitope of PD1, as compared to the native sequence of that B cell epitope.
- the functional variant differs from the native peptide sequence by one or more conservative amino acid substitutions.
- conservative amino acid substitution refers to changing amino acid identity at a given position to replace it with an amino acid of approximately equivalent size, charge and/or polarity.
- conservative substitutions of amino acids include the following 8 substitution groups (designated by the conventional one-letter code): (1) M, I, L, V; (2) F, Y, W; (3) K, R, (4) A, G; (5) S, T; (6) Q, N; (7) E, D; and (8) C, S.
- the functional variant has at least 85% sequence identity to an amino acid sequence of a B cell epitope of a native PD1 antigen.
- Reference to "at least 85%” includes 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity or similarity, for example, after optimal alignment or best fit analysis.
- the sequence has at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99% or preferably 100% sequence identity or sequence homology with the sequences identified herein, for example, after optimal alignment or best fit analysis.
- a functional variant includes amino acid substitutions and/or other modifications in order to increase the stability of the immunogen and/or to increase the solubility of the immunogen to enhance its ability to induce an antibody response in vivo. Suitable modifications will be familiar to persons skilled in the art, illustrative examples of which are described elsewhere herein.
- the immunogen may comprise a peptide sequence of any suitable length, as long as the peptide retains the ability or capacity, when administered to the subject in accordance with the methods disclosed herein, to induce an antibody response in which the antibody binds to a B cell epitope of native PD1.
- methods of determining whether a peptide sequence retains the ability or capacity, when administered, to induce an antibody response in which the antibody binds to a B cell epitope of native PD1 will be familiar to persons skilled in the art.
- the peptide sequence is at least 10 (e.g., 10, 11, 12, 13, 14, IS, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more) amino acids in length.
- the peptide sequence is from about 10 amino acids to about 40 amino acids in length. In an embodiment, the peptide sequence is from about 10 amino acids to about 35 amino acids in length. In an embodiment, the peptide sequence is from about 10 amino acids to about 30 amino acids in length. In an embodiment, the peptide sequence is from about 10 amino acids to about 25 amino acids in length. In an embodiment, the peptide sequence is from about 10 amino acids to about 20 amino acids in length. In an embodiment, the peptide sequence is from about 10 amino acids to about 15 amino acids in length.
- the immunogen will comprise at least one peptide sequence that is capable of inducing an antibody response in which the antibody binds to a B cell epitope of PD1, preferably of native PD1. This may be achieved by using peptide sequence comprising an amino acid sequence of a B cell epitope of PD1 (or a functional variant thereof), and/or a mimotope of a PD1 B cell epitope. In an embodiment disclosed herein, the immunogen comprises at least one mimotope of a B cell epitope of PD1.
- the term “mimotope” typically refers to a molecule that has a conformation that has a topology equivalent to the B cell epitope of which it is a mimic and binds to the same antigen-binding region of an antibody which binds immunospeciflcally to said B cell epitope.
- the mimotope will elicit an immunological response in a host that is reactive to the antigen to which it is a mimic.
- Mimotopes of PD1 B cell epitopes preferably are antigenic polypeptides which, in their amino acid sequence, vary from the amino acid sequence of a native B cell epitope of PD1.
- the mimotope may not only comprise amino acid substitutions of one or more naturally occurring amino acid residues of a native PD1 molecule, but also of one or more non-natural amino acids (i.e. not from the 20 "classical” amino acids) or they may be completely assembled of such non-natural amino acids.
- Suitable mimotopes may be provided from commercially available peptide libraries. Preferably, these mimotopes are at least 7 amino acids in length (e.g, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or more amino acids in length).
- Preferred lengths may be up to 16, preferably up to 14 or 20 amino acids (e.g. 5 to 16 amino acid residues). Longer mimotopes may also be employed. In an embodiment, the mimotope may be part of a polypeptide and consequently comprising at their N- and/or C -terminus at least one further amino acid residue.
- Peptide sequences disclosed herein can be synthetically produced by chemical synthesis methods which are well known in the art, either as an isolated peptide sequence or as a part of another peptide or polypeptide.
- peptide sequences can be produced in a microorganism which produces the (recombinant) peptide sequence or sequences, which can then be isolated and, if desired, further purified.
- the peptide sequences can be produced in microorganisms such as bacteria, yeast or fungi, in eukaryote cells such as a mammalian or an insect cell, or in a recombinant virus vector such as adenovirus, poxvirus, herpesvirus, Simliki forest virus, baculovirus, bacteriophage, Sindbis virus or sendai virus.
- Suitable bacteria for producing the peptide sequences will be familiar to persons skilled in the art, illustrative examples of which include E. coli, B.subtilis or any other bacterium that is capable of expressing the peptide sequences.
- yeast types for expressing the peptide sequences include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Candida, Pichia pastoris or any other yeast capable of expressing peptides.
- Corresponding methods are well known in the art.
- methods for isolating and purifying recombinantly produced peptide sequences are well known in the art and include, for example, gel filtration, affinity chromatography and ion exchange chromatography.
- a fusion polypeptide may be made wherein the at least one peptide sequence is translationally fused (covalently linked) to a heterologous polypeptide which enables isolation by affinity chromatography.
- Typical heterologous polypeptides are His-Tag (e.g. His 6 . 6 histidine residues), GST-Tag (Glutathione-S-transferase) etc.
- His-Tag e.g. His 6 . 6 histidine residues
- GST-Tag Glutathione-S-transferase
- the fusion polypeptide may comprise a cleavage site at the junction between the peptide sequence and the heterologous polypeptide.
- the cleavage site consists of an amino acid sequence that is cleaved with an enzyme specific for the amino acid sequence at the site (e.g. proteases).
- peptide sequences disclosed herein may be suitably modified at or nearby their N- and/or C -termini so that at said positions a cysteine residue is bound thereto.
- phage libraries and/or peptide libraries are also suitable, for instance, produced by means of combinatorial chemistry or obtained by means of high throughput screening techniques for the most varying structures (see, for example, Display: A Laboratory Manual by Carlos F. Barbas (Editor), et al. and Willats WG Phage display: practicalities and prospects. Plant Mol. Biol. 2002 December; 50(6): 837-54).
- the peptide sequences may be presented as a fusion protein.
- the term "fusion protein" typically refers to a polypeptide composed of two or more peptide sequences linked to one another.
- the fusion protein comprises is a non-native polypeptide sequence of two or more peptide sequences linked to one another. Suitable methods of linking peptide sequences will be familiar to persons skilled in the art, illustrative examples of which include peptide (amide) bonds and linkers.
- the immunogens disclosed herein may suitably comprise a fusion protein comprising, consisting, or consisting essentially of any combination of two or more PD1 B cell epitopes and/or mimotopes thereof, as herein described.
- the fusion protein comprises, consists, or consists essentially of at least two B cell epitopes of PD1, or functional variants thereof, as herein described.
- the fusion protein comprises, consists, or consists essentially of at least two non-contiguous B cell epitopes of PD1, or functional variants thereof, as herein described.
- the fusion protein comprises, consists, or consists essentially of at least three noncontiguous B cell epitopes of PD1, or functional variants thereof, as herein described.
- the fusion protein comprises, consists, or consists essentially of at least two mimotopes of B cell epitopes of PD1, as herein described. In another embodiment, the fusion protein comprises, consists, or consists essentially of at least three mimotopes of B cell epitopes of PD1, as herein described.
- immunogens comprising a fusion protein comprising, consisting of, or consisting essentially of at least one (e.g., 1, 2, 3, 4, 5, 6 or more) PD1 B cell epitope, or a functional variant thereof, as herein described, and at least one mimotope (e.g., 1, 2, 3, 4, 5, 6 or more) of a PD1 B cell epitope, as herein described.
- the fusion protein comprises one B cell epitope of PD1, or a functional variant thereof, as herein described, and one mimotope of a PD1 B cell epitope, as herein described.
- the fusion protein comprises two B cell epitopes of PD1, or functional variants thereof, as herein described, and one mimotope of a PD1 B cell epitope, as herein described.
- the fusion protein comprises one B cell epitope of PD1, or a functional variant thereof, as herein described, and two mimotopes of a PD1 B cell epitope, as herein described.
- the fusion protein comprises two B cell epitope of PD1, or a functional variant thereof, as herein described, and two mimotopes of a PD1 B cell epitope, as herein described.
- the fusion protein comprises three B cell epitopes of PD1, or functional variants thereof, as herein described, and two mimotopes of a PD1 B cell epitope, as herein described. In another embodiment, the fusion protein comprises three B cell epitopes of PD1, or functional variants thereof, as herein described, and two mimotopes of a PD1 B cell epitope, as herein described.
- immunogens comprising a fusion protein comprising, consisting or consisting essentially of at least two mimotopes ⁇ e.g., at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, preferably at least 9, more preferably at least 10 mimotopes) of one or more PD1 B cell epitope.
- the mimotopes may raise an antibody response in which the antibodies bind the same B cell epitope of PD1, or they may bind different B cell epitopes of PD1.
- the fusion protein comprises at least two mimotopes capable of inducing an antibody response in vivo in which the antibodies bind at least two PD1 B cell epitopes ⁇ e.g., at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, preferably at least 9, preferably at least 10 or more PD1 B cell epitopes).
- fusion proteins comprising at least two peptide sequences, as herein described, concatenated two or more times in tandem repeat.
- fusion proteins contemplated herein may comprise two or more tandem repeats of the peptide fragments listed in Tables 1 and 2 (i.e., SEQ ID NOs:2-109 or functional variants thereof).
- incorporating two or more different B cell epitopes and/or mimotopes into the fusion peptide, as herein described, may generate a more beneficial immune response by eliciting a higher antibody titre as compared to an immunogen comprising a single B cell epitope of PD1 or a mimotope thereof.
- the at least two peptide sequences comprise amino acid sequences found in nature (e.g., sequences derived from a B cell epitope of native PD1)
- the peptide sequences may be linked to one another within the fusion peptide in such a way as to ensure the fusion protein comprises an amino acid sequence that is not identical to a continuous stretch of at least 40 amino acid residues of native PD1.
- the at least two peptide sequences are B cell epitopes of human PD1 (e.g., SEQ ID NO:l)
- the fusion protein comprises a least two non-contiguous B cell epitopes of human PD1.
- the fusion protein comprises at least two B cell epitopes of PD1 (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or more non-contiguous B cell epitopes of PD1)
- the fusion protein may comprise at least two non-contiguous B cell epitopes of PD1 linked to one another, such that the at least two B cell epitopes of PD1 are non-contiguous in their native state; that is, in native PD1.
- the peptide sequence(s) of the immunogen may suitably be conjugated, coupled or otherwise attached to a carrier.
- the immunogen comprises a carrier.
- the carrier is immunogenic.
- immunogenic typically means that the carrier is capable of facilitating or enhancing a humoral immune response to the peptide sequence(s) to which it is conjugated, coupled or otherwise attached when compared to the absence of a carrier.
- Suitable carriers will be known to persons skilled in the art, illustrative examples of which include keyhole limpet hemocyanin (KLH), tetanus toxoid (TT), B subunit of cholera toxin (CT, CTB), heat labile toxin (LT) of E. coli and mutants thereof, lactic acid bacteria (LAB)/probiotic bacteria, bacterial ghost, a parasite-derived antigen such as an antigen from Toxoplasma gondii (see, for example, Wagner et at. Sci Rep. (2017); 7(1):15211, and Wagner et al., PLoS One.
- KLH keyhole limpet hemocyanin
- TT tetanus toxoid
- CT B subunit of cholera toxin
- LT heat labile toxin
- LAB lactic acid bacteria
- LAB lactic acid bacteria
- bacterial ghost a parasite-derived antigen such as an antigen from Toxoplasm
- the carrier is selected from the group consisting of keyhole limpet hemocyanin (KLH), tetanus toxoid (TT), B subunit of cholera toxin (CT, CTB), heat labile toxin (LT) of E.
- KLH keyhole limpet hemocyanin
- TT tetanus toxoid
- CT CCT
- CTB heat labile toxin
- coli and mutants thereof lactic acid bacteria (LAB)/probiotic bacteria, bacterial ghost, a parasite-derived antigen, liposome, chitosome, virosome, a virus-like particle, and diphtheria toxin variant CRM-197.
- the carrier is not a virus-like particle.
- the vaccine compsition does not comprise a virus-like particle.
- the carrier is diphtheria toxin variant CRM-197 (SEQ ID NO: 118).
- CRM-197 GenBank Accession No. 1007216A; SEQ ID NO: 118
- Gly-Glu amino acid substitution
- a single GCA mutation that leads to the Glu52 substitution distinguishes CRM-197 from its wild-type species.
- the absence of toxicity of CRM-197 appears to be due to the loss of enzymatic activity of its fragment A, which in the wild-type species catalyzes the chemical modification of elongation factor 2 (translocase) in infected cells that is essential for protein synthesis.
- This non-toxic property makes CRM- 197 a suitable carrier protein for the preparation of conjugated vaccines.
- Conjugation of the peptide sequence(s), as disclosed herein, to a carrier is typically achieved through activation of the lysyl residues using suitable crosslinkers.
- suitable crosslinkers For instance, since CRM- 197 contains 40 lysines residues, and many of them are available for crosslinking, the end products of CRM- 197 conjugation are invariably heterogeneous. Without being bound by theory or a particular mod of action, it is generally understood that the ratio of the peptide sequence(s) to the carrier depends on the size or molecular weight of the peptide sequence(s).
- the immunogen comprises from 2 to 39 peptide sequences conjugated, coupled or otherwise attached to the carrier.
- the immunogen comprises at least 20 peptide sequences conjugated, coupled or otherwise attached to the carrier.
- the immunogen comprises from 6 to 12 peptide sequences conjugated, coupled or otherwise attached to the carrier.
- the peptide sequence(s) of the immunogen can be conjugated, coupled or otherwise attached to the carrier by a covalent bond.
- the peptide sequence(s) may be coupled to the carrier by a non-covalent association.
- the non-covalent association will typically involve an electromagnetic interaction between one or more atoms of the peptide sequence(s) with one or more atoms of the carrier.
- Illustrative examples include ionic bonding ⁇ i.e., the attraction formed between two oppositely charged ions by virtue of this opposite charge), Van der Weals forces ⁇ i.e., forces between permanent and/or induced dipoles of existing covalent bonds within the fusion protein and the carrier) and/or hydrophobic interactions ⁇ i.e., forces resulting from the tendency of hydrophobic/aliphatic portions within the peptide sequence(s) or fusion protein(s), as herein described, to associate with hydrophobic portions of the carrier).
- the peptide epitope is conjugated to a carrier.
- linker-mediated coupling from the C-terminus of the peptide epitope, since linker coupling from the N-terminus may, in some instances, have a negative influence on the desired immune response to be elicited.
- the carrier is immunogenic.
- the carrier is selected from the group consisting of keyhole limpet hemocyanin (KLH), tetanus toxoid (TT), B subunit of cholera toxin (CT, CTB), heat labile toxin (LT) of E. coli and mutants thereof, lactic acid bacteria (LAB), bacterial ghost, liposome, chitosome, virosome, virus-like particle, dendritic cell and diphtheria toxin variant CRM-197.
- the carrier is not a virus-like particle.
- the vaccine compsition does not comprise a virus-like particle.
- the carrier is diphtheria toxin variant CRM- 197 (SEQ ID NO:58).
- CRM-197 (GenBank Accession No. 1007216A; SEQ ID NO:58) is an enzymatically inactive and nontoxic form of diphtheria toxin that contains a single amino acid substitution (Gly-Glu) at amino acid residue 52.
- Gly-Glu amino acid substitution
- a single GCA mutation that leads to the Glu52 substitution distinguishes CRM-197 from its wild-type species.
- the absence of toxicity of CRM-197 appears to be due to the loss of enzymatic activity of its fragment A, which in the wild-type species catalyzes the chemical modification of elongation factor 2 (translocase) in infected cells that is essential for protein synthesis.
- This non-toxic property makes CRM-197 a suitable carrier protein for the preparation of conjugated vaccines.
- Conjugation of a peptide epitope, as herein described, to CRM- 197 is typically achieved through activation of the lysyl residues using suitable crosslinkers. Since CRM- 197 contains 40 lysines residues, and many of them are available for crosslinking, the end products of CRM- 197 conjugation are invariably heterogeneous. Without being bound by theory or a particular mod of action, it is generally understood that the ratio of the immunogen to carrier protein depends on the size or molecular weight of the immunogen. For instance, where the immunogen is relatively small ⁇ e.g., 12-24 amino acids in length), it may be possible to produce a carrier that is conjugated with 20-39 immunogens.
- the carrier may be conjugated with up to, or fewer than, 20 immunogens.
- the carrier comprises from 2 to 39 immunogens.
- the carrier comprises at least 20 immunogens.
- the carrier comprises from 6 to 12 immunogens.
- the immunogen can be coupled to the carrier by a covalent bond.
- the immunogen may be coupled to the carrier by a non-covalent association.
- the non- covalent association will typically involve an electromagnetic interaction between one or more atoms of the immunogen with one or more atoms of the carrier.
- Illustrative examples include ionic bonding ⁇ i.e., the attraction formed between two oppositely charged ions by virtue of this opposite charge), Van der Weals forces ⁇ i.e., forces between permanent and/or induced dipoles of existing covalent bonds within the peptide epitope and the carrier) and/or hydrophobic interactions ⁇ i.e., forces resulting from the tendency of hydrophobic/aliphatic portions within the peptide epitope (s), as herein described, to associate with hydrophobic portions of the carrier).
- Adjuvant ⁇ i.e., the attraction formed between two oppositely charged ions by virtue of this opposite charge
- Van der Weals forces ⁇ i.e., forces between permanent and/or induced dipoles of existing covalent bonds within the peptide epitope and the carrier
- hydrophobic interactions i.e., forces resulting from the tendency of hydrophobic/aliphatic portions within the peptide epitope (s), as herein described, to associate with hydrophobic portions of the carrier).
- the vaccine composition disclosed herein may suitably be formulated with an adjuvant to further enhance the antibody response to PD1.
- the vaccine composition disclosed herein comprises an adjuvant.
- adjuvant typically refers to a class of substance that can increase the magnitude of the immune (antibody) response elicited by the immunogen beyond that which would be expected from the immunogen alone.
- Suitable adjuvants will be known to persons skilled in the art, illustrative examples of which include aluminium salts (e.g. aluminium hydroxide, aluminium phosphate and potassium aluminium sulfate (also referred to as Alum)), liposomes, virosomes, water-in-oil or oil-in-water emulsions (e.g. Freund's incomplete adjuvant, Montanide®, MF59® and AS03), 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and adjuvants containing MPL (e.g.
- aluminium salts e.g. aluminium hydroxide, aluminium phosphate and potassium aluminium sulfate (also referred to as Alum)
- liposomes e.g. aluminium hydroxide, aluminium phosphate and potassium aluminium sulfate (also referred to as Alum)
- liposomes e.g. aluminium hydroxide, aluminium phosphate
- AS01, AS02 and AS04 toll-like receptor agonists (see, e.g., Kaczanowska et al., 2013, J. Leukoc. Biol. 93(6):847-863; the entire contents of which are incorporated herein by reference), squalene and saponin-based adjuvants.
- Saponin-based adjuvants include saponins or saponin derivatives from, for example, Quillaja saponaria, Panax ginseng Panax notoginseng, Panax quinquefolium, Platycodon grandiflorum, Polygala senega, Polygala tenuifolia, Quillaja brasiliensis, Astragalus membranaceus and Achyranthes bidentata.
- Exemplary saponin-based adjuvants include iscoms, iscom matrix, ISCOMATRIXTM adjuvant, Matrix MTM adjuvant, Matrix CTM adjuvant, Matrix QTM adjuvant, AbLSCO®-100 adjuvant, AbISCO®-300 adjuvant, ISCOPREPTM, an ISCOPREPTM derivative, adjuvant containing ISCOPREPTM or an ISCOPREPTM derivative, QS-21, a QS-21 derivative, and an adjuvant containing QS-21 or a QS21 derivative.
- cytokines include cytokines, chemokines and growth factors, illustrative examples of which include GM-CSF, interleukins (e.g., IL-1, IL-2, IL-5, IL:-7, EL-8, IL-10, IL-12, IL-15, IL-18 and IL-21), tumour necrosis factor (TNF), interferon (e.g., IFN- ⁇ ), transforming growth factor (e.g., TGF- ⁇ ), RANTES, MIPl- ⁇ , MCP-1, heat-shock proteins (e.g., HSP70), C-type lectin receptor agonists (e.g., Mincle, Dectin-1, Dectin-2 and CLEC9A) and retinoic acid-inducible gene I (RIG-l)-like receptor ligands (e.g., RIG-I and melanoma differentiation-associated gene 5 (MDAS)) and Toll-like receptor ligands or agonist
- Suitable Toll-like receptor ligands will be familiar to persons skilled in the art, illustrative examples of which include monophosphoryl lipid A (3-0-desacyl-4'- monophosphoryl lipid A; MPL), bacterial lipoprotein, Pam 3 CSK 4 , Poly I:C, Poly ICLC, glucopyranosyl lipid A-stable emulsions, and CpG ODN.
- MPL monophosphoryl lipid A
- MPL monophosphoryl lipid A
- bacterial lipoprotein Pam 3 CSK 4
- Poly I:C Poly I:C
- Poly ICLC Poly ICLC
- glucopyranosyl lipid A-stable emulsions and CpG ODN.
- Other examples of Toll-like receptor ligands are disclosed in Steinhagen et al. (2011, Vaccine, 29(17):3341-3355), the entire contents of which are incorporated herein by reference.
- the adjuvant is selected from the group consisting of aluminium hydroxide, aluminium phosphate, potassium aluminium sulfate, calcium phosphate hydroxide, a saponin, a TLR agonist, CRM 197, a water-in-oil emulsion, an oil-in-water emulsion, Freund's incomplete adjuvant, MF59, a CpG oligonucleotide, iscoms, iscom matrix, monophosphoryl lipid A ((3-0-desacyl-4'- monophosphoryl lipid A; MPL), AS01 (a liposome-based formulation of MPL and QS-21), AS04 (a liposome-based formulation of MPL and aluminium hydroxide), QS-21, a QS-21 derivative, an adjuvant containing QS-21 or a QS21 derivative, and a combination of any of the foregoing.
- MPL monophosphoryl lipid A
- AS01 a liposome-based formulation of MPL and QS-21
- AS04
- the adjuvant is a TLR-4 agonist.
- the TLR-4 agonist is monophosphoryl lipid A.
- the adjuvant is Montanide.
- the TLR-4 agonist is AS01 (a liposome-based formulation of MPL and QS-21).
- the adjuvant is AS04 (a liposome-based formulation of MPL and aluminium hydroxide).
- the adjuvant is selected from the group consisting of aluminium hydroxide, aluminium phosphate and potassium aluminium sulfate.
- the composition further comprises an adjuvant.
- adjuvant typically refers to a class of substance that can increase the magnitude of the immune response elicited by the immunogen beyond that which would be expected, either from the immunogen alone or from the immunogen- carrier conjugate, as herein described, in the absence of an adjuvant.
- Suitable adjuvants will be known to persons skilled in the art.
- suitable adjuvants include aluminium salts (e.g. aluminium hydroxide, aluminium phosphate and potassium aluminium sulfate (also referred to as Alum)), liposomes, virosomes, water-in-oil or oil-in-water emulsions (e.g. Freund's adjuvant, Montanide®, MF59® and AS03), 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and adjuvants containing MPL (e.g. AS01, AS02 and AS04) and saponin-based adjuvants.
- aluminium salts e.g. aluminium hydroxide, aluminium phosphate and potassium aluminium sulfate (also referred to as Alum)
- liposomes e.g. aluminium hydroxide, aluminium phosphate and potassium aluminium sulfate (also referred to as Alum)
- Saponin-based adjuvants include saponins or saponin derivatives from, for example, QuiUaja saponaria, Panax ginseng Panax notoginseng, Panax quinquefolium, Platycodon grandiflorum, Polygala senega, Polygala tenuifolia, Quillaja brasiliensis, Astragalus membranaceus and Achyranthes bidentata.
- Exemplary saponin-based adjuvants include iscoms, iscom matrix, ISCOMATRIXTM adjuvant, Matrix MTM adjuvant, Matrix CTM adjuvant, Matrix QTM adjuvant, AbISCO®-100 adjuvant, AbISCO®-300 adjuvant, ISCOPREPTM, an ISCOPREPTM derivative, adjuvant containing ISCOPREPTM or an ISCOPREPTM derivative, QS-21, a QS-21 derivative, and an adjuvant containing QS-21 or a QS21 derivative.
- the vaccine composition as herein described can also be associated with immumodulatory agents, including, for example, cytokines, chemokines and growth factors. Mixtures of two or more adjuvants within the same vaccine composition are also contemplated herein.
- the adjuvant is selected from the group consisting of aluminium hydroxide, aluminium phosphate, potassium aluminium sulfate, calcium phosphate hydroxide, a saponin, Freund's complete adjuvant, a TLR agonist, CRM 197, Montanide®, Freund's incomplete adjuvant, MF59, a CpG oligonucleotide, iscoms, iscom matrix, ISCOMATRIXTM adjuvant, Matrix MTM adjuvant, Matrix CTM adjuvant, Matrix QTM adjuvant, AbISCO®-100 adjuvant, AbISCO®-300 adjuvant, ISCOPREPTM, an ISCOPREPTM derivative, adjuvant containing ISCOPREPTM or an ISCOPREPTM derivative, monophosphoryl lipid A ((3-0-desacyl-4'-monophosphoryl lipid A; MPL), AS01 (a liposome-based formulation of MPL and QS-21), AS04 (a
- the adjuvant is a TLR-4 agonist.
- the TLR-4 agonist is monophosphoryl lipid A.
- the adjuvant is Montanide.
- the TLR-4 agonist is AS01 (a liposome-based formulation of MPL and QS-21).
- the adjuvant is AS04 (a liposome-based formulation of MPL and aluminium hydroxide).
- the present disclosure also extends to the use of a combination of adjuvants and/or carriers.
- the present inventors have surprisingly found that immunization with a peptide sequence of a B cell epitope of the checkpoint antigen PD1 is capable of raising an antibody response in which the antibodies bind to the native PDl protein. It was also surprisingly found that immunization with the PDl -derived B cell epitope did not appear to give rise to adverse side effects that are sometimes evident with the passive administration of antibodies to checkpoint antigens.
- a method of treating a cancer characterised by an involvement of programmed cell death protein 1 comprising administering to a subject a vaccine composition for raising a humoral response to PDl, wherein the vaccine composition comprises an effective amount of an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PDl.
- PDl programmed cell death protein 1
- cancer and “tumour” are used interchangeably herein and will be understood as comprising malignant cells; also referred to as neoplastic cells, cancer cells or tumour cells.
- malignant cell is meant an abnormal cell that grows by uncontrolled cellular proliferation and will typically continues to grow after the initial growth stimulus has ceased.
- cancer characterised by an involvement of PDl is meant a cancer in which PDl is involved, at least in part, in an endogenous inhibitory pathway responsible for downregulaling the immune response towards the cancer.
- cancers that are characterised by an involvement of PDl.
- Illustrative examples include malignancies such as melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, Hodgkin's lymphoma, gastric cancer, pancreatic cancer, prostate cancer and salivary gland cancer.
- the cancer is non-small cell lung cancer.
- the cancer is melanoma.
- the cancer is gastric cancer.
- the methods described herein are directed to vaccine compositions for the treatment of a cancer characterised by an involvement of PD1.
- Other illustrative examples include leukemias, seminomas, teratomas, neuroblastomas, gliomas, rectal cancer, endometrial cancer, kidney cancer, adrenal cancer, thyroid cancer, blood cancer, skin cancer, cancer of the brain, cervical cancer, intestinal cancer, liver cancer, colon cancer, stomach cancer, intestine cancer, head and neck cancer, gastrointestinal cancer, lymph node cancer, esophagus cancer, colorectal cancer, pancreas cancer, ear, nose and throat (ENT) cancer, breast cancer, prostate cancer, cancer of the uterus, ovarian cancer, and lung cancer, lung carcinomas, prostate carcinomas, colon carcinomas, cervical carcinomas and the metastases thereof.
- ENT nose and throat
- the cancer is characterized by the presence of malignant cells in which a cancer-associated antigen, as described elsewhere herein, is expressed or aberrantly expressed (e.g., overexpressed) by the malignant cells or tissue.
- a cancer-associated antigen as described elsewhere herein, is expressed or aberrantly expressed (e.g., overexpressed) by the malignant cells or tissue.
- the cancer is characterized by surface expression of the cancer-associated antigen.
- aberrant or abnormal expression is meant that expression of the cancer-associated antigen is altered, preferably increased, compared to the state in a non-malignant or normal cell or in a healthy individual (i.e., in an individual not having a disease associated with aberrant or abnormal expression of the antigen).
- the increase in expression of the cancer-associated antigen refers to an increase by at least 10%, preferably by at least 20%, preferably by at least 50%, preferably by at least 100%, or more.
- aberrant or abnormal expression of the cancer-associated antigen means that the antigen is only detectable on the cancer cells or tissue, while expression in normal or healthy tissue is undetectable.
- the vaccine composition as described herein, is formulated for administration to a subject in need thereof to provide the immunogen in an "effective amount"; that is, an amount effective to elicit any one or more inter alia of a therapeutic effect.
- an effective amount that is, an amount effective to elicit any one or more inter alia of a therapeutic effect.
- Persons skilled in the art would be able, by routine experimentation, to determine an effective, non-toxic amount to administer for the desired outcome.
- the vaccine composition as disclosed herein, can be administered in a manner compatible with the route of administration and physical characteristics of the recipient (including health status) and in such a way that it elicits the desired effect(s) (i.e. therapeutic effect).
- the appropriate dosage of a composition may depend on a variety of factors including, but not limited to, a subject's physical characteristics ⁇ e.g., age, weight, sex), whether the composition is being used as single agent or as part of adjunct therapy (e.g., with a second immunogen directed to a cancer-associated antigen, as described elsewhere herein), the progression (i.e., pathological state) of any underlying cancer, and other factors that may be recognized by persons skilled in the art.
- a subject's physical characteristics e.g., age, weight, sex
- adjunct therapy e.g., with a second immunogen directed to a cancer-associated antigen, as described elsewhere herein
- the progression i.e., pathological state
- An effective amount of the immunogen to be administered will generally be in a range of from about 5 g to about 1.0 mg of immunogen per subject, from about 10 g to about 500 g of immunogen per subject, or from about IS g to about 60 ⁇ g of immunogen per subject.
- An effective amount can be ascertained, for example, by standard methods involving measurement of antigen-specific antibody litres.
- the level of immunity provided by the compositions herein described can be monitored to determine the need, if any, for boosters. For instance, following an assessment of an antigen-specific antibody litre in the serum, typically days or weeks following the first administration of the composition in a subject, optional booster immunisations may be required and/or desired.
- the optimal quantity and spacing of individual dosages, if required to induce the desired immune response can be determined, for example, by the form, route and site of administration, and the nature of the particular subject to be treated, as is described elsewhere herein. Optimum conditions can be determined using conventional techniques known to persons skilled in the art. In some instances, it may be desirable to have several or multiple administrations of the vaccine and/or pharmaceutical compositions, as herein described. For example, the compositions may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times. The administrations may be from about one day intervals to about twelve week intervals, and in certain embodiments from about one to about four week intervals.
- Periodic re- administration may be required to achieve a desirable therapeutic result, such as a reduction in tumour size and/or a reduction in the occurrence of metastases. It will also be apparent to persons skilled in the art that the optimal course of administration can be ascertained using conventional course of treatment or efficacy or immune status determination tests.
- inducing includes eliciting or stimulating an immune response and/or enhancing a previously existing immune response to obtaining a desired therapeutic effect, such as a reduction in tumour size, a slowing of tumour growth and/or a reduction in the occurrence of metastases.
- a desired therapeutic effect such as a reduction in tumour size, a slowing of tumour growth and/or a reduction in the occurrence of metastases.
- the effect can also be prophylactic in terms of, for example, completely or partially preventing the occurrence of metastases.
- the terms “administration” or “admimstering” typically refer to the step of introducing the vaccine and/or pharmaceutical compositions, as herein described, into a patient's body so that the patient's immune system mounts a response to the peptide sequences within the fusion protein.
- a "subject in need thereof includes an individual who has been diagnosed with cancer. In its broadest sense, the term "a patient in need thereof therefore encompasses individuals with an already present need, as well as individuals who are at risk of developing cancer.
- treating are also used interchangeably herein to mean relieving, reducing, alleviating, ameliorating or otherwise inhibiting the progression of cancer in a subject, including one or more symptoms thereof.
- the terms “treating”, “treatment” and the like are also used interchangeably herein to mean preventing cancer from occurring or delaying the onset or subsequent progression of cancer in a subject that may be predisposed to, or at risk of, cancer, but has not yet been diagnosed as having it.
- the terms “treating”, “treatment” and the like are used interchangeably with terms such as “prophylaxis", “prophylactic” and “preventive”.
- a medicament which "treats" cancer will ideally eliminate the disease altogether by eliminating its underlying cause so that, upon cessation of administration of the composition, the disease does not re-develop, but remains in remission.
- a medicament which "ameliorates” cancer does not eliminate the underlying cause of the disease, but reduces the severity of the disease as measured by any established grading system and/or as measured by an improvement in the patient's well-being, e.g. decrease in pain and/or discomfort.
- adjunct therapies for treating cancer by using one or more additional therapeutic agents.
- a second immunogen as herein described, can provide an enhance immune response for the treatment of a cancer in the subject.
- the methods disclosed herein further comprise administering to the subject a second immunogen in an effective amount to induce an immune response against a checkpoint antigen other than PD1.
- the methods disclosed herein further comprise administering to the subject a second immunogen in an effective amount to induce an immune response against a cancer- associated antigen.
- the immune response induced by the second immunogen may suitably comprise a T cell response ⁇ e.g., CTL), a B cell response, or both.
- the second immunogen may comprise at least one B cell epitope of a checkpoint antigen other than PD1 and/or of a cancer-associated antigen (and/or mimotopes thereof), such that when administered to the subject in an effective amount, is capable of inducing an antibody (B cell) response against the checkpoint antigen and/or the cancer-associated antigen.
- the second immunogen is administered to the subject in an effective amount to induce an antibody (B cell) response.
- the second immunogen is administered to the subject in an effective amount to induce an antibody response in which the antibody binds to a B cell epitope of a cancer-associated antigen. In another embodiment, the second immunogen is administered to the subject in an effective amount to induce an antibody response in which the antibody binds to a B cell epitope of a checkpoint antigen other than PD1. In an embodiment, the second immunogen comprises at least one B cell epitope of a checkpoint antigen other than PD1 and/or of a cancer- associated antigen. In another embodiment, the second immunogen comprises a mimotope that is capable of inducing an antibody response in which the antibody binds to a B cell epitope of a checkpoint antigen other than PD1 and/or of a cancer-associated antigen.
- the second immunogen may comprise at least one T cell epitope of a checkpoint antigen other than PD1 and/or of a cancer-associated antigen, such that when administered to the subject in an effective amount, is capable of inducing a T cell ⁇ e.g., CTL) response against the checkpoint antigen and/or the cancer-associated antigen.
- the second immunogen is administered to the subject in an effective amount to induce a T cell response against checkpoint antigen other than PD1.
- the second immunogen is administered to the subject in an effective amount to induce a T cell response against a cancer-associated antigen.
- the second immunogen comprises at least one T cell epitope of a cancer- associated antigen.
- the second immunogen comprises at least one T cell epitope of a checkpoint antigen other than PD1.
- the second immunogen comprises at least one B cell epitope of a cancer-associated antigen, or a mimotope thereof, and at least one T cell epitope of a cancer-associated antigen, such that when administered to the subject in an effective amount, is capable of inducing an antibody response and a T cell response against the cancer-associated antigen.
- the at least one T cell epitope and the at least one B cell epitope, or mimotope thereof may suitably be derived from the same cancer-associated antigen, such that when the second immunogen is administered to the subject in an effective amount, it is capable of inducing an antibody response and a T cell response against the same cancer-associated antigen.
- the at least one T cell epitope and the at least one B cell epitope, or mimotope thereof may suitably be derived from different cancer-associated antigens, such that when the second immunogen is administered to the subject in an effective amount, it is capable of inducing an antibody response and a T cell response against each of the different cancer-associated antigens.
- checkpoint antigens other than PD1 will be familiar to persons skilled in the art, illustrative examples of which are discussed by Pardoll (2012, Nature Reviews Cancer 12:252-64).
- Other illustrative examples of suitable checkpoint antigens include CTLA-4 (cytotoxic T lymphocyte antigen-4) and its ligands CD80 and CD86; PD-Ll (programmed cell death ligand 1), PD-L2 (programmed cell death ligand 2), LAG-3 (lymphocyte activation gene-3) and its ligand MHC class I or II, TIM-3 (T cell immunoglobulin and mucin protein-3) and its ligand GAL-9, B- and T-lymphocyte attenuator (BTLA) and its ligand herpes virus entry mediator (HVEM) and several others, as discussed, for example, by Nirschl & Drake (2013 Clin Cancer Res 19:4917-24).
- the checkpoint antigen other than PD1 is selected from CTLA-4 (cytotoxic T lymph
- checkpoint antigen is understood to mean an antigen that is involved in endogenous inhibitory pathways for immune system function, such as those that act to maintain self-tolerance and modulate the duration and extent of immune response to antigenic stimulation.
- cancer-associated antigen means an antigen that is aberrantly expressed in cancer cells or tissue.
- the antigen may be expressed under normal conditions in a limited number of tissues and/or organs or in specific developmental stages.
- the antigen may be specifically expressed under normal conditions in stomach tissue and is expressed or aberrantly expressed ⁇ e.g., overexpressed) in one or more cancer cells.
- the expression of antigen may be reactivated in cancer cells or tissue irrespective of the origin of the cancer.
- the cancer-associated antigen includes differentiation antigens, preferably cell type-specific differentiation antigens ⁇ i.e., proteins that are specifically expressed under normal conditions in a certain cell type at a certain differentiation stage), cancer/testis antigens ⁇ i.e., proteins that are specifically expressed under normal conditions in testis and sometimes in placenta), and germline specific antigens.
- differentiation antigens preferably cell type-specific differentiation antigens ⁇ i.e., proteins that are specifically expressed under normal conditions in a certain cell type at a certain differentiation stage
- cancer/testis antigens i.e., proteins that are specifically expressed under normal conditions in testis and sometimes in placenta
- germline specific antigens preferably germline specific antigens.
- the antigen associated with cancer is expressed on the cell surface of a cancer cell and is preferably not or only rarely expressed on normal cells and tissues.
- the antigen or the aberrant expression of the antigen identifies cancer cells, preferably tumour cells.
- the antigen that is expressed by a cancer cell in a subject ⁇ e.g., a patient suffering from cancer
- the antigen that is expressed by a cancer cell in a subject is a self-protein. It will be understood, however, that no autoantibodies directed against the antigen are typically found in a detectable level under normal conditions in a subject carrying the antigen (typically a healthy patient that does not have cancer) or such autoantibodies can only be found in an amount below a threshold concentration that would be necessary to damage the tissue or cells carrying the antigen.
- Suitable cancer-associated antigens will be known to persons skilled in the art, illustrative examples of which include EGFR ⁇ e.g., Her2/neu, Her-1), BAGE (B melanoma antigen), CEA (carcinoembryonic antigen), Cpg (cytosine- phosphate diesterguanine), GplOO (glycoprotein 100), h-TERT (telomerase transcriptase), MAGE (melanoma antigen-encoding gene), Melan-A (melanoma antigen recognized by T cells) and MUC-1 (mucin- 1).
- EGFR ⁇ e.g., Her2/neu, Her-1
- BAGE B melanoma antigen
- CEA carcinoembryonic antigen
- Cpg cytosine- phosphate diesterguanine
- GplOO glycoprotein 100
- h-TERT telomerase transcriptase
- MAGE melanoma antigen-encoding gene
- the cancer-associated antigen is selected from the group consisting of EGFR ⁇ e.g., Her2/neu, Her-1), BAGE (B melanoma antigen), CEA (carcinoembryonic antigen), CpG (cytosine-phosphate diesterguanine), GplOO (glycoprotein 100), h-TERT (telomerase transcriptase), MAGE (melanoma antigen- encoding gene), Melan-A (melanoma antigen recognized by T cells) and MUC-1 (mucin- 1).
- EGFR ⁇ e.g., Her2/neu, Her-1
- BAGE B melanoma antigen
- CEA carcinoembryonic antigen
- CpG cytosine-phosphate diesterguanine
- GplOO glycoprotein 100
- h-TERT telomerase transcriptase
- MAGE melanoma antigen- encoding gene
- Melan-A melanoma antigen recognized by T cells
- the antigen will typically be an antigen that is associated with ⁇ e.g., overexpressed by) the breast cancer.
- Suitable examples of antigens associated with breast cancer will be familiar to persons skilled in the art, illustrative examples of which include the epidermal growth factor receptors Her2/neu and Herl.
- the amino acid sequence of the checkpoint antigen other than PD1 and/or the cancer-associated antigen is identical between the antigen as it is expressed in normal tissues and the antigen as it is expressed in cancer cells or tissue.
- the amino acid sequence of the checkpoint antigen other than PD1 and/or the cancer-associated antigen comprises a mutation in its amino acid sequence when compared to the amino acid sequence of the native antigen as it would otherwise be expressed in normal tissue or cells.
- the ability of the second immunogen, as herein described, to improve the efficacy of the vaccine composition by raising an immune response to the checkpoint antigen other than PD1 and/or the cancer-associated antigen does not require the second immunogen to be present in the vaccine composition with the PDl-targeted immunogen, or to be administered simultaneously with the PD1 -targeted immunogen to a subject in need thereof.
- the second immunogen as herein described, can be administered prior, or subsequent, to the administration of the PDl- targeted immunogen, wherein the period of time between administering the PDl-targeted immunogen and administering the second immunogen can be optimised to provide the desired synergistic or additive effect.
- the terms "normal tissue” or "normal conditions” typically refer to healthy tissue or the conditions in a healthy subject; that is, non-pathological conditions, wherein "healthy” preferably means non-tumorigenic or non-cancerous.
- the term "specifically expressed” typically means that the antigen is only, or predominantly, expressed in a specific tissue or organ.
- a antigen specifically expressed in breast tissue means that the antigen is primarily expressed in breast tissue and is not expressed in other tissues or is not expressed to a significant extent in other tissue or organs.
- an antigen that is exclusively expressed in cells of breast tissue and to a significantly lesser extent in any other tissue, such as the gastric mucosa is specifically expressed in cells of breast tissue.
- the antigen may also be specifically expressed under normal conditions in more than one tissue type or organ ⁇ e.g., 2, 3, 4, 5, 6 or more) tissue types or organs. For example, if an antigen associated with cancer is expressed under normal conditions to an approximately equal extent in breast and stomach tissue, the antigen is considered to be specifically expressed in breast and stomach tissue.
- self protein means a protein that is encoded by the genome of the subject and that is under normal conditions (i.e., non-pathological conditions) optionally expressed in certain normal tissue types or at certain stages of development.
- the method further comprises administering to the subject one or more additional therapeutic agents that specifically target a malignant cell.
- the vaccine compositions described herein further comprise one or more additional therapeutic agents or compounds that specifically target a malignant cell.
- additional therapeutic agents will be known to persons skilled in the art, illustrative examples of which include antibodies that specifically bind to a checkpoint antigen and/or a cancer-associated antigen, or an antigen-binding fragment thereof.
- the methods disclosed herein further comprises administering to the subject an antibody that specifically binds to a cancer-associated antigen, or an antigen-binding fragment thereof, as described elsewhere herein.
- the methods disclosed herein further comprise administering to the subject an antibody that specifically binds to a checkpoint antigen, or an antigen-binding fragment thereof, as described elsewhere herein.
- the antibody or an antigen-binding fragment specifically binds to a checkpoint antigen other than PD1.
- the antibody or an antigen-binding fragment specifically binds to PD1.
- a vaccine composition in the preparation of a medicament for the treatment of a cancer characterised by an involvement of PD1, wherein the vaccine composition comprises an effective amount of an immunogen for inducing an antibody response in which the antibody binds to a B cell epitope of PD1, as herein described.
- a vaccine composition for use in treating a cancer characterised by an involvement of PD1, wherein the vaccine composition comprises an effective amount of an immunogen for inducing an antibody response in which the antibody binds to a B cell epitope of PD1, as herein described.
- a vaccine composition for raising a humoral response to PD1 wherein the vaccine composition comprises an effective amount of an immunogen for inducing an antibody response in which the antibody binds to a B cell epitope of PD1, as herein described.
- the vaccine pharmaceutical compositions described herein comprise a pharmaceutically acceptable excipient.
- suitable pharmaceutically acceptable excipients e.g. carriers, diluents, etc.
- aqueous (pharmaceutically acceptable) excipients may be used, such as buffered water, 0.4% saline, 0.3% glycine, hyaluronic acid and the like.
- These compositions may be sterilized by conventional, well known sterilization techniques or may be sterile-filtered.
- the resulting aqueous solutions may be packaged for use as is or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.
- compositions may further comprise pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH- adjusting and buffering agents, tonicity-adjusting agents, wetting agents and the like, for example sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, sucrose or other carbohydrates, among many others.
- auxiliary substances such as pH- adjusting and buffering agents, tonicity-adjusting agents, wetting agents and the like, for example sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, sucrose or other carbohydrates, among many others.
- Suitable methods for preparing parenterally administrable compounds will be known or apparent to those skilled in the art and are described in more detail in, for example, A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy", 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery
- the vaccine composition may be prepared in a form suitable for parenteral administration ⁇ e.g., subcutaneous, intramuscular or intravenous injection) or in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation.
- parenteral administration e.g., subcutaneous, intramuscular or intravenous injection
- aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation.
- the vaccine compositions described herein may also be provided in a kit.
- the kit may comprise additional components to assist in performing the methods as herein described, such as administration device(s), excipients(s), carrier(s) and/or diluent(s).
- the kits may include containers for housing the various components and instructions for using the kit components in such methods.
- the vaccine composition further comprises a second immunogen in an effective amount for inducing an immune response against a checkpoint antigen other than PD1 and/or a cancer-associated antigen, as described elsewhere herein.
- the vaccine composition further comprises an antibody that specifically binds to a checkpoint antigen and/or a cancer-associated antigen, or an antigen-binding fragment thereof, as described elsewhere herein.
- the vaccine composition further comprises one or more additional therapeutic agents that specifically target a malignant cell, as described elsewhere herein.
- the vaccine composition may further comprise at least one B cell epitope and/or mimotope of a cancer-associated antigen.
- the vaccine composition further comprises at least one B cell epitope and/or mimotope of a cancer-associated antigen such that the peptide epitope and the at least one B cell epitope and/or mimotope of a cancer-associated antigen are present in the same composition.
- the ability of the at least one B cell epitope and/or mimotope of a cancer-associated antigen to improve the efficacy of the peptide epitope disclosed herein, by raising an antibody response to the cancer-associated antigen does not require the at least one B cell epitope and/or mimotope of a cancer-associated antigen to be present in the vaccine composition with the peptide epitope or to be administered simultaneously to a subject in need thereof.
- the at least one B cell epitope and/or mimotope of a cancer-associated antigen can be administered prior or subsequent to the administration of the peptide epitope, wherein the period of time between administering the vaccine composition and administering the at least one B cell epitope and/or mimotope of a cancer-associated antigen can be optimised to provide the desired synergistic or additive effect.
- cancer-associated antigen As noted elsewhere herein, the terms “cancer-associated antigen”, “antigen associated with cancer, “tumour-associated antigen”, “tumour antigen”, “cancer antigen” and the like are used interchangeably herein to mean an antigen that is aberrantly expressed in cancer cells or tissue.
- the antigen may be expressed under normal conditions in a limited number of tissues and/or organs or in specific developmental stages.
- the antigen may be specifically expressed under normal conditions in stomach tissue and is expressed or aberrantly expressed ⁇ e.g., overexpressed) in one or more cancer cells.
- the expression of antigen may be reactivated in cancer cells or tissue irrespective of the origin of the cancer.
- the cancer-associated antigen includes differentiation antigens, preferably cell type-specific differentiation antigens (i.e., proteins that are specifically expressed under normal conditions in a certain cell type at a certain differentiation stage), cancer/testis antigens (i.e., proteins that are specifically expressed under normal conditions in testis and sometimes in placenta), and germline specific antigens.
- the antigen associated with cancer is expressed on the cell surface of a cancer cell and is preferably not or only rarely expressed on normal cells and tissues.
- the antigen or the aberrant expression of the antigen identifies cancer cells, preferably tumour cells.
- the antigen that is expressed by a cancer cell in a subject is a self-protein. It will be understood, however, that no autoantibodies directed against the antigen are typically found in a detectable level under normal conditions in a subject carrying the antigen (typically a healthy patient that does not have cancer) or such autoantibodies can only be found in an amount below a threshold concentration that would be necessary to damage the tissue or cells carrying the antigen.
- the amino acid sequence of the cancer-associated antigen is identical between the antigen as it is expressed in normal tissues and the antigen as it is expressed in cancer cells or tissue.
- the cancer-associated antigen comprises a mutation in its amino acid sequence when compared to the amino acid sequence of the cancer-associated antigen as it would otherwise be expressed in normal tissue or cells.
- suitable cancers include leukemias, seminomas, melanomas, teratomas, lymphomas, neuroblastomas, gliomas, rectal cancer, endometrial cancer, kidney cancer, adrenal cancer, thyroid cancer, blood cancer, skin cancer, cancer of the brain, cervical cancer, intestinal cancer, liver cancer, colon cancer, stomach cancer, intestine cancer, head and neck cancer, gastrointestinal cancer, lymph node cancer, esophagus cancer, colorectal cancer, pancreas cancer, ear, nose and throat (ENT) cancer, breast cancer, prostate cancer, cancer of the uterus, ovarian cancer, and lung cancer, lung carcinomas, prostate carcinomas, colon carcinomas, renal cell carcinomas, cervical carcinomas and the metastases thereof.
- ENT nose and throat
- the term “mimotope” typically refers to a molecule that has a conformation that has a topology equivalent to the B cell epitope of which it is a mimic and binds to the same antigen-binding region of an antibody which binds immunospecifically to said B cell epitope.
- the mimotope will elicit an immunological response in a host that is reactive to the antigen to which it is a mimic.
- Mimotopes of a cancer-associated antigen are preferably antigenic polypeptides that, in their amino acid sequence, vary from the amino acid sequence of a native cancer- associated antigen.
- the mimotope may not only comprise amino acid substitutions of one or more naturally occurring amino acid residues of a native cancer-associated antigen, but also of one or more non-natural amino acids (i.e. not from the 20 "classical” amino acids) or they may be completely assembled of such non-natural amino acids.
- Suitable mimotopes may be provided from commercially available peptide libraries. Preferably, these mimotopes are at least 7 amino acids in length (e.g, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or more amino acids in length).
- Preferred lengths may be up to 16, preferably up to 14 or 20 amino acids (e.g. 5 to 16 amino acid residues). Longer mimotopes may also be employed. In an embodiment, the mimotope may be part of a polypeptide and consequently comprising at their N- and/or C-terminus at least one further amino acid residue.
- a pharmaceutical composition comprising the vaccine composition as herein described and a pharmaceutically acceptable excipient.
- Suitable pharmaceutically acceptable excipients e.g. carriers, diluents, etc.
- aqueous excipients such as buffered water, 0.4% saline, 0.3% glycine, hyaluronic acid and the like.
- These compositions may be sterilized by conventional, well known sterilization techniques or may be sterile-filtered.
- the resulting aqueous solutions may be packaged for use as is or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.
- compositions may further comprise pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity- adjusting agents, wetting agents and the like, for example sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, sucrose or other carbohydrates, among many others.
- auxiliary substances such as pH-adjusting and buffering agents, tonicity- adjusting agents, wetting agents and the like, for example sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, sucrose or other carbohydrates, among many others.
- Suitable methods for preparing parenterally administrable compounds will be known or apparent to those skilled in the art and are described in more detail in, for example, A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy", 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery
- the pharmaceutical composition may be in a form suitable for parenteral administration ⁇ e.g., subcutaneous, intramuscular or intravenous injection) or in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation.
- parenteral administration e.g., subcutaneous, intramuscular or intravenous injection
- aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation.
- kits may comprise additional components to assist in performing the methods as herein described, such as administration device(s), excipients(s), carrier(s) and/or diluent(s).
- the kits may include containers for housing the various components and instructions for using the kit components in such methods.
- the pharmaceutic composition further comprises a checkpoint antigen or a checkpoint inhibitor, as herein described.
- a method of treating a condition characterised by an involvement of PD1 comprising administering to a subject in need thereof the vaccine composition as herein described or the pharmaceutical composition as herein described.
- the present disclosure also extends to use of the vaccine composition, as herein described, in the manufacture of a medicament for treating a condition characterized by an involvement of PD1 in a subject in need thereof.
- the present disclosure also extends to the vaccine composition, as herein described, or the pharmaceutical composition, as herein described, for use in treating a condition characterized by an involvement of PD1 in a subject in need thereof.
- the condition characterised by an involvement of PD1 is cancer.
- Illustrative examples include malignancies such as melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, Hodgkin's lymphoma,, gastric cancer, pancreatic cancer, prostate cancer and salivary gland cancer.
- the cancer is non-small cell lung cancer.
- the cancer is melanoma.
- the cancer is gastric cancer.
- the vaccine or pharmaceutical compositions, as described herein, are typically administered in an "effective amount"; that is, an amount effective to elicit any one or more inter alia of a therapeutic effect.
- an effective amount that is, an amount effective to elicit any one or more inter alia of a therapeutic effect.
- Persons skilled in the art would be able, by routine experimentation, to determine an effective, non-toxic amount to administer for the desired outcome.
- the vaccine and/or pharmaceutical compositions, as disclosed herein can be administered in a manner compatible with the route of administration and physical characteristics of the recipient (including health status) and in such a way that it elicits the desired effect(s) (i.e. therapeutic effect).
- the appropriate dosage of a composition may depend on a variety of factors including, but not limited to, a subject's physical characteristics (e.g., age, weight, sex), whether the composition is being used as single agent or as part of adjunct therapy (e.g., with a checkpoint antigen or checkpoint inhibitor), the progression (i.e., pathological state) of any underlying cancer, and other factors that may be recognized by persons skilled in the art.
- a subject's physical characteristics e.g., age, weight, sex
- adjunct therapy e.g., with a checkpoint antigen or checkpoint inhibitor
- progression i.e., pathological state
- An effective amount of the peptide epitope to be administered will generally be in a range of from about 5 ⁇ g to about 5.0 mg of peptide sequence per subject, preferably from about 500 g to about 5.0mg of peptide epitope per subject, preferably from about 10 g to about 500 g of peptide epitope per subject, or from about 15 ⁇ g to about 60 ⁇ g of peptide epitope per subject.
- An effective amount can be ascertained, for example, by standard methods involving measurement of antigen-specific antibody titres.
- the level of immunity provided by the compositions herein described can be monitored to determine the need, if any, for boosters.
- the immunogen may be administered to the subject in a range from about 5 g to about 5.0 mg of immunogen per subject, preferably from about 500 g to about 5.0mg of immunogen per subject, or preferably from about 1mg to about 5mg of immunogen per subject.
- the vaccine and/or pharmaceutical compositions can be administered to a subject in need thereof in isolation or in combination with additional therapeutic agent(s); that is, as part of an adjunct therapy.
- the administration may be simultaneous or sequential; that is, the vaccine and/or pharmaceutical composition is administered first, followed by administration of the additional therapeutic and/or prophylactic agent(s), or the vaccine and/or pharmaceutical composition is administered following the administration of the additional therapeutic agent(s).
- two or more entities are administered to a subject "in conjunction" they may be administered in a single composition at the same lime, or in separate compositions at the same time, or in separate compositions separated in time.
- the additional therapeutic agent(s) may comprise a checkpoint inhibitor.
- checkpoint antigen typically means an antigen that is involved in endogenous inhibitory pathways for immune system function, such as those that act to maintain self-tolerance and modulate the duration and extent of immune response to antigenic stimulation. Studies have shown, however, checkpoint antigens reduce the effectiveness of a host's immune response towards the cancer, resulting in tumour growth (see Nirschl & Drake, 2013, Clin Cancer Res 19:4917-24). Suitable checkpoint antigens will be familiar to persons skilled in the art, illustrative examples of which are discussed by Pardoll (2012, Nature Reviews Cancer 12:252-64).
- checkpoint antigens include CTLA-4 (cytotoxic T lymphocyte antigen-4) and its ligands CD80 and CD86; PD-L1 (programmed cell death ligand 1), PD-L2 (programmed cell death ligand 2), LAG-3 (lymphocyte activation gene- 3) and its ligand MHC class I or ⁇ , ⁇ -3 (T cell immunoglobulin and mucin protein-3) and its ligand GAL-9, B- and T-lymphocyte attenuator (BTLA) and its ligand herpes virus entry mediator (HVEM) and several others, as discussed, for example, by Nirschl & Drake (2013 Clin Cancer Res 19:4917-24).
- CTLA-4 cytotoxic T lymphocyte antigen-4
- PD-L1 programmeed cell death ligand 1
- PD-L2 programmeed cell death ligand 2
- LAG-3 lymphocyte activation gene-3
- ligand MHC class I or ⁇ , ⁇ -3 T cell
- the vaccine composition may target multiple antigens; that is, in addition to PD1.
- the peptide epitope may further comprise one or more B cell epitopes and/or mimotopes of one or more cancer-associated antigens such that the peptide epitope, when administered, will induce an antibody response to PD1 and the one or more cancer- associated antigens (e.g., 2, 3, 4, 5, 6, 7 or more cancer-associated antigens).
- the peptide epitope comprises one or more B cell epitopes and/or mimotopes of one or more additional checkpoint antigen (other than PD1) such that the peptide epitope, when administered, will induce an antibody response directed against the one or more additional checkpoint antigen (e.g., 1, 2, 3, 4, 5, 6, 7 or more checkpoint antigens other than PD1).
- additional checkpoint antigen e.g., 1, 2, 3, 4, 5, 6, 7 or more checkpoint antigens other than PD1
- the methods disclosed herein further comprise administering to the subject an antibody that specifically binds to a cancer-associated antigen, or an antigen-binding fragment thereof.
- the cancer-associated antigen is selected from the group consisting of Her2/neu, Her-1, B melanoma antigen (BAGE), carcinoembryonic antigen (CEA), cytosine-phosphate diesterguanine (CpG), glycoprotein 100 (GplOO), telomerase transcriptase (h-TERT), melanoma antigen- encoding gene (MAGE), melanoma antigen recognized by T cells (Melan-A) and mucin- 1 (MUC-1).
- the antibody or antigen-binding fragment thereof is administered to the subject subsequent to the administration of the vaccine composition.
- the optimal quantity and spacing of individual dosages, if required to induce the desired immune response can be determined, for example, by the form, route and site of administration, and the nature of the particular subject to be treated, as is described elsewhere herein. Optimum conditions can be determined using conventional techniques known to persons skilled in the art.
- the compositions may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times.
- the administrations may be from about one day intervals to about twelve week intervals, and in certain embodiments from about one to about four week intervals.
- Periodic re- administration may be required to achieve a desirable therapeutic result, such as a reduction in tumour size and/or a reduction in the occurrence of metastases. It will also be apparent to persons skilled in the art that the optimal course of administration can be ascertained using conventional course of treatment or efficacy or immune status determination tests.
- inducing includes eliciting or stimulating an immune response and/or enhancing a previously existing immune response to obtaining a desired therapeutic effect, such as a reduction in tumour size, a slowing of tumour growth and/or a reduction in the occurrence of metastases.
- a desired therapeutic effect such as a reduction in tumour size, a slowing of tumour growth and/or a reduction in the occurrence of metastases.
- the effect can also be prophylactic in terms of, for example, completely or partially preventing the occurrence of metastases.
- the terms “administration” or “admimstering” typically refer to the step of introducing the vaccine and/or pharmaceutical compositions, as herein described, into a patient's body so that the patient's immune system mounts a response to the peptide sequences within the peptide epitope.
- a "subject in need thereof includes an individual who has been diagnosed with cancer. In its broadest sense, the term "a patient in need thereof therefore encompasses individuals with an already present need, as well as individuals who are at risk of developing cancer.
- a medicament which "treats" cancer will ideally eliminate the disease altogether by eliminating its underlying cause so that, upon cessation of administration of the composition, the disease does not re-develop, but remains in remission.
- a medicament which "ameliorates” cancer does not eliminate the underlying cause of the disease, but reduces the severity of the disease as measured by any established grading system and/or as measured by an improvement in the patient's well-being, e.g. decrease in pain and/or discomfort.
- the vaccine compositions can be administered to a subject in need thereof in isolation or in combination with one or more additional therapeutic agents; that is, as part of an adjunct therapy.
- the administration may be simultaneous or sequential; that is, the vaccine composition is administered first, followed by administration of one or more additional therapeutic agents, or the vaccine composition is administered following the administration of the additional therapeutic agent(s).
- two or more entities are administered to a subject "in conjunction" they may be administered in a single composition at the same time, or in separate compositions at the same time, or in separate compositions separated in time.
- mice PD1 epitope were identified as a surrogate to a human PD1 epitope, or a mimotope therof, which would allow for subsequent tests to be conducted in a syngeneic mouse tumour model, as outlined in Example 3, below.
- the protein sequence corresponding to the extracellular domain of mouse PD-1 was electronically back-translated into DNA sequences (ATG:Biosynthelics GmbH; Merzhausen, Germany).
- the protein-coding DNA sequences were partitioned into uniformly sized peptide-CDS as overlapping peptides in 15 amino acids (aa) length, with an offset of 3 aa, and the resulted DNA sequences were inserted into the expression vector pEPX-1 (ATG:Biosynthetics GmbH; Merzhausen, Germany).
- GST Glutathione S-transferases
- clones of interest were replicated onto nitrocellulose membranes and lysed with lysis solution (Tris-HCl pH 8.0 50 mM, Lysozyme 200 ⁇ ), followed by three cycles of freezing at -80C and thawing at 37C. After the last step of thawing, the membranes were incubated with the blocking solution containing PBS-5% skim milk. The blocking solution was discarded and the membranes were incubated for 2h at RT with rat anti-mouse PD1 monoclonal antibody (mAb) (Biolegend, clone 29F.1A12).
- mAb monoclonal antibody
- the membranes were then washed three times with PBS-Tween 0.0.5%, and incubated for 2h at RT with the secondary antibody Goat Anti-rat IgG conjugated to Alkaline Phosphatase (Santa Cruz Biotechnology). After additional washing as above, the signals were developed using the substrate solution ⁇ -Step NBT/BCIP' (Thermo Scientific). The following PD1 B cell epitope was identified as being reactive to the rat anti-mouse PD1 monoclonal antibody:
- Bacterial culture of a clone expressing the B cell epitope candidate was used for preparation of cytosolic and total fraction of bacterial lysates. Two equal portions of the bacterial culture were centrifuged, and the bacterial pellets were lysed as above. Lysed bacteria were either further centrifuged and the supernatant was used as cytosolic fraction, or the lysed bacteria were used directly as total fraction.
- the examined lysates were spotted onto nitrocellulose membranes for use in a dot blot assay. After blocking of the membranes with PBS-2% skim milk, the membranes were reacted with the monoclonal antibody (mAb), which had been used for detection of the positive clones in the colony blot assay, and the remaining procedures for detection were also as similar to the colony blot assay.
- mAb monoclonal antibody
- the 0.22 urn-filtrated cytosolic fraction containing the GST-fused B cell epitope of interest was used for purification using 5 ml Glutathione Sepharose 4B (GSTrap; GE Healthcare), using freshly prepared elution buffer (50 mM Tris-HCl pH 8.0, containing 10 mM of reduced glutathione). The eluted material was examined by dot blot analysis as described as above and the purity of the materials as visualized by SDS-PAGE analysis. E. SDS-Page analysis
- a competitive ELISA was employed to examine the capacity of the identified B cell epitope in inhibiting the binding of the anti-mouse-PDl mAb to recombinant mouse PD1 used as coating antigen, onto which preincubated mixtures containing different concentrations of the mimotope and the mAb were applied.
- Anti-mouse PD-1 mAb bound to the coated recombinant mPDl was detected using the secondary antibody mouse anti- Rat IgG (H+L) (Jackson Immunoresearch Laboratories; HRP-conjugated), and using TMB staining for detection (ELISA OD values, 450 nm). The results are shown in Figure 9.
- T cell stimulator cells based on the K562 cell line (K562S), were generated by retrovirally transducing a CD5L-OKT3scFv-CD14 construct encoding an anti-human CD3 single chain fragment fused to human CD 14 (Leitner et al. J. Immunol Methods, 2010, 362(1-2):131-141; PMID: 20858499).
- K562S stimulate human T cells and T cell lines by ligating their TCR-CD3 complex.
- K562S were engineered to constitutively express a red fluorescent protein (RFP). Single cell clones were established to assure homogenous and comparable expression of the respective molecules.
- RFP red fluorescent protein
- a PE-conjugated anti-mPD-1 antibody (29F.1A12) from Biolegend (San Diego, CA) was used.
- Membrane-bound anti-CD3 fragment on K562S cells was detected with a PE-conjugated goat-anti-mouse IgG (H+L) antibody (Jackson ImmunoResearch, West Grove, PA).
- FACS Calibur with CellQuest software both BD Biosciences, San Jose, CA.
- Data was analysed using FlowJo software (version 10.0.8., Tree Star, Ashland, OR) and Graphpad Prism (version 5, GraphPad Software, Inc., La Jolla, CA).
- mice Male Balb/C mice (Charles River, Sulzfeld, Germany; 6-8 week of age at the time of delivery) were grafted with different amounts of the cells:
- tumour size was measured during the experiment and after the mice were sacrificed, with the results showing a significant increase in tumour size over the study period.
- Example 2 Binding of anti-mPDl monoclonal antibodies to mPDl is inhibited in the presence of the mouse PD1 B cell epitope, JT-mPDl (SEQ ID NO: 119)
- mice Female Balb/C mice (Charles River, Sulzfeld, Germany; 6-8 week of age at the time of delivery) were used in an experimental setting including intraperitoneal administration of CRM-conjugated B cell epitope (Provepharm), together with Alum as adjuvant.
- CRM-conjugated B cell epitope Provepharm
- the conjugated PD1 B cell epitope was diluted with NaCl solution and mixed with Alum prior injection.
- Six immunizations were carried out in 3 weeks intervals, and blood samples were taken prior each immunization and three weeks after the last immunization when the mice were sacrificed.
- mice received a 1 st intraperitoneal dose of CRM alone or the mPDl B cell epitope-CRM conjugate (10 ⁇ g or 50 ⁇ g) at day 1.
- Subsequent doses of CRM alone or the mPDl B cell epitope-CRM conjugate were administered on day 21 (2 nd dose), day 42 (3 rd dose), day 63 (4 th dose), and day 84 (5 th dose).
- Blood samples were taken from the mice on day 0 (Pre Bleeding-BAO), day 41 (BA1), day 62 (BA2), day 83 (BA3), and day 104 (BA4). Animals were sacrificed on day 105.
- mice immunised with the mPDl B cell epitope-CRM conjugate showed a clear antibody response to the mPDl-CRM conjugate, as illustrated by an increased titre of anti- mPDl IgG antibodies at 41 days (BA1), 62 days (BA2), 83 days (BA3) and 104 days (BA4) after the first immunization at day 0 ( Figure 4).
- the mice immunised with either CRM alone or the mPDl B cell epitope-CRM conjugate showed no adverse side effects, changes in body weight or any sign of inflammation.
- Example 4 Specific IgG antibodies raised against JT-mPDl block the mPDl/mPDLl interaction in vitro
- the mPDl B cell epitope (SEQ ID NO: 119; JT-mPDl) was investigated to examine whether antibodies raised against this peptide can bind to native mPDl and inhibit its interaction with mouse PDL1.
- mice were immunized at Charles River (France) by subcutaneous administration of 200 ⁇ g of the mPDl B cell epitope (JT-mPDl) conjugated to keyhole limpet hemocyanin (KLH), followed by three additional doses at three weeks intervals. The rabbits were sacrificed two weeks after the fourth and final dose. Total and JT-PD1 -specific IgG were isolated from the sera of immunised rabbits at Squarix (Germany).
- JT-mPDl mPDl B cell epitope
- KLH keyhole limpet hemocyanin
- the mPDl B cell epitope (JT-mPDl; SEQ ID NO:119) was further investigated to determine whether antibodies raised against this peptide can bind to mPDl and inhibit the interaction of mPDl with its ligand, mouse PDL1.
- anti-JT-mPDl IgG did not bind to control (mPDl -negative) Jurkat cells, whereas the anti-JT-mPDl. IgG dose- dependently bound to mPDl+ Jurkat cells.
- mice were grafted with mammary carcinoma cell line D2F2/E2, as described in Example 3, above. Animals then received either PBS (PBS controls), total rabbit IgG isolated from non-imminised rabbits (IgG controls) or anti-JT-mPDl IgG. As shown in Figure 7, while similar tumor weights were observed in PBS- or rabbit IgG-treated mice, a significant reduction in tumor weight was observed in the mice treated with anti-JT-mPDl or with anti-mPDl mAb. These results show that PD1 B cell epitopes can be used in a vaccine composition to raise an anti-PDl antibody response in vivo, wherein the anti-PDl antibodies inhibit the growth of established tumors.
- Example 6 Screening a library of peptide sequences by ELISA for B cell epitopes of PD1
- a library of biotinylated peptide fragments of those listed in Table 1 (SEQ ID NOs:2-54 and 62) was generated and subsequently screened by enzyme-linked immunosorbent assays (ELISA) on streptavidin-coated plates using a polyclonal anti-PDl antibody to identify peptide fragments to which the anti-PDl antibody bound.
- ELISA enzyme-linked immunosorbent assays
- Biotinylated peptide fragments were supplied as a dry powder and reconstituted in 200 ⁇ L of either a pure solvent ⁇ e.g. dimethyl sulfoxide or dimethyl formamide) or solvent/water mixture. Each biotinylated peptide fragment was diluted just before use to a working concentration of 1:1000 in phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) and 0.1% sodium azide.
- PBS phosphate buffered saline
- BSA bovine serum albumin
- the plates were then washed four times with PBS (0.01M sodium phosphate in 0.15M sodium chloride, pH7.2) containing 0.1% v/v Tween 20. After the washing steps, excess wash buffer was removed from the wells. The plates were then allowed to dry at 37°C. [0236]
- the anti-PDl polyclonal antibody (Sino Biological Inc.; Cat. No. 10377-RP03; a rabbit polyclonal antibody raised against recombinant human PD1/CD279) was diluted in 2%BS A/PBS containing 0.1% sodium azide.
- the absorbance of any colour change in each well was read using a microtitre Titertek Multiskan MC plate reader in the dual wavelength mode at 405nm against a reference wavelength of 492nm and compared to appropriate negative controls, such as the colour change observed in a well to which no biotinylated peptide fragment was added, to which no anti-PDl polyclonal antibody was added and/or to which no horseradish peroxidase-labeled, anti-rabbit antibody was added.
- KLH Keyhole limpet hemocyanin
- each KLH-conjugated peptide fragment was diluted with saline and subsequently emulsified in complete or incomplete Freund's adjuvant at a mass ratio of 1:1.
- the emulsified solution was administered to rabbits by subcutaneous injection around the shoulders and intramuscular injection into the legs in accordance with the following immunization protocol:
- ELISA enzyme-linked immunosorbent assays
- Example 10 Comparison of the cross-reactivity of anti-PDl antibodies derived from immunized rabbits to PD1 of other species
- Affinity purified anti-PDl antibodies raised to the peptides and fusion peptides of SEQ ID NO:9 (sera no. 2809001), SEQ ID NO:43 (sera no. 2809025) and SEQ ID NO:57 (sera no. 2916503), were screened for binding to PDl protein of different species (all antibodies were diluted 1/100).
- the inventors screened a library of 54 linear peptide fragments of human PDl (12-mer, offset by 3 amino acids) and identified a total of 13 peptide sequences to which the anti-PDl polyclonal antibodies bound.
- the 13 peptide sequences were each conjugated to a carrier protein (KLH) and the KLH- conjugated peptides were subsequently injected into rabbits.
- Andsera from the immunised rabbits were collected and anti-PDl antibodies were affinity purified from the antisera and screened for binding to native human PD1.
- the inventors unexpectedly found that of the 13 peptide conjugates that were used to immunised the rabbits, only 9 conjugates generated sufficient anti-PDl antibody titres - SEQ ID NOs:9, 10, 14, 28, 29, 49, 59, 61 and 43. Of the 9 peptide sequences that raised a marked anti-PDl antibody titre in the immunised rabbits, SEQ ID NO:9 generated the highest anti-PDl antibody titre. Anti-PDl antibodies were also raised in animals immunized with fusion peptides comprising SEQ ID NO:9 and SEQ ED NO:43 (SEQ ID NO:56 and SEQ ID NO:57).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980024131.4A CN112203681B (en) | 2018-02-07 | 2019-02-07 | Vaccine composition and use thereof |
EP19751452.4A EP3749356A4 (en) | 2018-02-07 | 2019-02-07 | A vaccine composition and uses thereof |
US16/966,442 US20210236614A1 (en) | 2018-02-07 | 2019-02-07 | Vaccine composition and uses thereof |
JP2020564972A JP2021512966A (en) | 2018-02-07 | 2019-02-07 | Vaccine composition and its use |
AU2019216873A AU2019216873A1 (en) | 2018-02-07 | 2019-02-07 | A vaccine composition and uses thereof |
CA3090552A CA3090552A1 (en) | 2018-02-07 | 2019-02-07 | A vaccine composition and uses thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018900368A AU2018900368A0 (en) | 2018-02-07 | A vaccine composition and uses thereof | |
AU2018900368 | 2018-02-07 | ||
AU2018903518A AU2018903518A0 (en) | 2018-09-19 | A vaccine composition and uses thereof | |
AU2018903518 | 2018-09-19 | ||
AU2018903968A AU2018903968A0 (en) | 2018-10-19 | A vaccine composition and uses thereof | |
AU2018903968 | 2018-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019153042A1 true WO2019153042A1 (en) | 2019-08-15 |
Family
ID=67547868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2019/050089 WO2019153042A1 (en) | 2018-02-07 | 2019-02-07 | A vaccine composition and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210236614A1 (en) |
EP (1) | EP3749356A4 (en) |
JP (1) | JP2021512966A (en) |
CN (1) | CN112203681B (en) |
AU (1) | AU2019216873A1 (en) |
CA (1) | CA3090552A1 (en) |
WO (1) | WO2019153042A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023026881A1 (en) * | 2021-08-25 | 2023-03-02 | 東亞合成株式会社 | Anti-pd-1 signal peptide antibody and use thereof |
KR102401860B1 (en) * | 2021-10-21 | 2022-05-24 | 을지대학교 산학협력단 | Novel anti-cancer vaccine composition and vaccination method using same |
KR102421307B1 (en) * | 2021-11-19 | 2022-07-14 | 을지대학교 산학협력단 | Novel anti-cancer vaccine composition for inhibiting cancer occurrence and growth and vaccination method using same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016106159A1 (en) * | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holding, Inc. | Anti-pd-1 antibodies |
WO2016183469A1 (en) * | 2015-05-13 | 2016-11-17 | Robert Kirken | Anti-ctla-4 blockade |
WO2017040790A1 (en) * | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
WO2018183488A1 (en) * | 2017-03-28 | 2018-10-04 | Ohio State Innovation Foundation | Human pd1 peptide vaccines and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007053455A2 (en) * | 2005-10-28 | 2007-05-10 | Vaxinnate Corporation | Polypeptide ligans for toll-like receptor 4 (tlr4) |
US20120082687A1 (en) * | 2010-10-04 | 2012-04-05 | Alex Wah Hin Yeung | Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use |
CA2863695C (en) * | 2012-02-16 | 2023-01-17 | Vlp Therapeutics, Llc | Virus like particle composition |
CA3004695C (en) * | 2012-04-30 | 2020-08-04 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
US10047137B2 (en) * | 2013-04-05 | 2018-08-14 | Versitech Limited | Antibodies against novel PD1 isoforms and uses thereof |
US9637532B2 (en) * | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
US9969986B2 (en) * | 2014-08-08 | 2018-05-15 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
BR112017021981A2 (en) * | 2015-04-17 | 2018-07-10 | Biolife Science Qld Limited | vaccine composition and uses |
-
2019
- 2019-02-07 CN CN201980024131.4A patent/CN112203681B/en active Active
- 2019-02-07 US US16/966,442 patent/US20210236614A1/en active Pending
- 2019-02-07 WO PCT/AU2019/050089 patent/WO2019153042A1/en unknown
- 2019-02-07 AU AU2019216873A patent/AU2019216873A1/en active Pending
- 2019-02-07 JP JP2020564972A patent/JP2021512966A/en active Pending
- 2019-02-07 CA CA3090552A patent/CA3090552A1/en active Pending
- 2019-02-07 EP EP19751452.4A patent/EP3749356A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016106159A1 (en) * | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holding, Inc. | Anti-pd-1 antibodies |
WO2016183469A1 (en) * | 2015-05-13 | 2016-11-17 | Robert Kirken | Anti-ctla-4 blockade |
WO2017040790A1 (en) * | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
WO2018183488A1 (en) * | 2017-03-28 | 2018-10-04 | Ohio State Innovation Foundation | Human pd1 peptide vaccines and uses thereof |
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
US20210236614A1 (en) | 2021-08-05 |
CN112203681B (en) | 2024-05-24 |
EP3749356A1 (en) | 2020-12-16 |
CA3090552A1 (en) | 2019-08-15 |
CN112203681A (en) | 2021-01-08 |
JP2021512966A (en) | 2021-05-20 |
AU2019216873A1 (en) | 2020-08-20 |
EP3749356A4 (en) | 2021-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10166276B2 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
PT2155243E (en) | Compositions and methods comprising klk3, psca, or folh1 antigen | |
US8258261B2 (en) | Induction of tumor immunity by variants of folate binding protein | |
US20210236614A1 (en) | Vaccine composition and uses thereof | |
JP2010532656A (en) | Fusion protein containing cancer regression antigens NY-ESO-1 and LAGE-1 | |
CA2763486A1 (en) | Casb7439 constructs | |
MXPA01007148A (en) | Use of antibodies for anticancer vaccination. | |
US10532090B2 (en) | Vaccine composition and uses thereof | |
EP1467751A2 (en) | Immunogenic cea | |
US20080241177A1 (en) | Idiotypic vaccine | |
US11154599B2 (en) | Her2/neu immunogenic composition | |
US20180264093A1 (en) | Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof | |
US20210346484A1 (en) | Method of producing a vaccine composition and uses thereof | |
CN113318225A (en) | Tumor immunopotentiator and its preparation method and application | |
WO2008040759A1 (en) | Method for down-regulation of cripto | |
JP2018520152A (en) | Immunogenic preprocalcitonin peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19751452 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3090552 Country of ref document: CA Ref document number: 2020564972 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019216873 Country of ref document: AU Date of ref document: 20190207 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019751452 Country of ref document: EP Effective date: 20200907 |